Liposcience (LPDX) 10-Q 8 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 05, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'LIPOSCIENCE INC	'
Entity Central Index Key	'0001168197	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	15,162,970

Balance_Sheets

Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$51,574	$24,768
Accounts receivable, net	6,511	5,149
Inventories	212	125
Prepaid expenses and other	878	719
Total current assets	59,175	30,761
Property and equipment, net	12,580	11,493
Other noncurrent assets:	'	'
Restricted cash	502	1,505
Intangible assets, net of accumulated amortization of $144 and $147 at September 30, 2013 and December 31, 2012, respectively	764	637
Deferred financing costs	74	100
Deferred offering costs	0	3,151
Other assets	63	32
Total other noncurrent assets	1,403	5,425
Total assets	73,158	47,679
Current liabilities:	'	'
Accounts payable	1,807	1,003
Accrued expenses	3,820	5,349
Revolving line of credit	0	5,000
Current maturities of long-term debt	3,904	0
Total current liabilities	9,531	11,352
Long-term liabilities:	'	'
Long-term debt, less current maturities	11,884	15,708
Preferred stock warrant liability	0	412
Other long-term liabilities	2,636	2,462
Total liabilities	24,051	29,934
Redeemable Convertible Preferred Stock:	'	'
Series D, D-1, E and F Redeemable Convertible Preferred Stock, par value $.001; 15,216,336 shares designated and 11,205,672 issued and outstanding at December 31, 2012; aggregate liquidation preference of $51,695	0	57,301
Stockholders’ equity (deficit):	'	'
Series A, A-1, B, B-1, C and C-1 Convertible Preferred Stock, par value $.001; 3,428,677 shares designated and 1,687,010 shares issued and outstanding at December 31, 2012; aggregate liquidation preference of $7,472	0	1
Common stock, $.001 par value; 75,000,000 and 90,000,000 shares authorized at September 30, 2013 and December 31, 2012, respectively; 14,900,262 and 1,894,277 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively	15	2
Additional paid-in capital	107,004	8,434
Accumulated deficit	-57,912	-47,993
Total stockholders’ equity (deficit)	49,107	-39,556
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)	73,158	47,679
Redeemable Convertible Preferred Stock [Member]	'	'
Redeemable Convertible Preferred Stock:	'	'
Series D, D-1, E and F Redeemable Convertible Preferred Stock, par value $.001; 15,216,336 shares designated and 11,205,672 issued and outstanding at December 31, 2012; aggregate liquidation preference of $51,695	$0	$57,301

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Accumulated amortization	$144	$147
Convertible preferred stock, par value (in usd per share)	$0.00	$0.00
Convertible preferred stock, shares designated	'	3,428,677
Convertible preferred stock, shares issued	'	1,687,010
Convertible preferred stock, shares outstanding	'	1,687,010
Convertible preferred stock, aggregate liquidation preference	'	7,472
Common stock, par value (in usd per share)	$0.00	$0.00
Common stock, shares authorized	75,000,000	90,000,000
Common stock, shares issued	14,900,262	1,894,277
Common stock, shares outstanding	14,900,262	1,894,277
Redeemable Convertible Preferred Stock [Member]	'	'
Redeemable convertible preferred stock, par value (in usd per share)	$0.00	$0.00
Redeemable convertible preferred stock, shares designated	'	15,216,336
Redeemable convertible preferred stock, shares issued	'	11,205,672
Redeemable convertible preferred stock, shares outstanding	'	11,205,672
Redeemable convertible preferred stock, aggregate liquidation preference	'	$51,695

Statements_of_Comprehensive_Lo

Statements of Comprehensive (Loss) Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues	$12,738	$13,564	$39,665	$41,241
Cost of revenues	2,608	2,627	8,074	7,622
Gross profit	10,130	10,937	31,591	33,619
Operating expenses:	'	'	'	'
Research and development	3,389	2,533	9,639	7,448
Sales and marketing	7,616	5,908	21,077	16,746
General and administrative	3,304	2,710	9,381	7,764
Total operating expenses	14,309	11,151	40,097	31,958
(Loss) income from operations	-4,179	-214	-8,506	1,661
Other expense:	'	'	'	'
Interest income	27	4	74	9
Interest expense	-473	-141	-1,471	-370
Other (expense) income	-2	-130	-16	-243
Total other expense	-448	-267	-1,413	-604
Net (loss) income	-4,627	-481	-9,919	1,057
Net (loss) income attributable to common stockholders – basic	-4,627	-481	-9,919	207
Net (loss) income attributable to common stockholders – diluted	-4,627	-481	-9,919	329
Net (loss) income per share attributable to common stockholders - basic (in usd per share)	($0.31)	($0.28)	($0.67)	$0.12
Net (loss) income per share attributable to common stockholders - diluted (in usd per share)	($0.31)	($0.28)	($0.67)	$0.10
Weighted average shares used to compute basic net (loss) income per share attributable to common stockholders	14,727,286	1,704,689	14,727,286	1,704,689
Weighted average shares used to compute diluted net (loss) income per share attributable to common stockholders	14,727,286	1,704,689	14,727,286	3,151,102
Comprehensive (loss) income	-4,627	-481	-9,919	1,057
Preferred Stock [Member]	'	'	'	'
Other expense:	'	'	'	'
Undistributed earnings allocated	0	0	0	-850
Common Stock [Member]	'	'	'	'
Other expense:	'	'	'	'
Undistributed earnings allocated	$0	$0	$0	$122

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Operating activities	'	'
Net (loss) income	($9,919)	$1,057
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:	'	'
Depreciation and amortization	1,196	950
Amortization of deferred financing costs	27	0
Amortization of debt discount	80	0
Stock-based compensation expense	1,065	881
Fair value remeasurement of preferred stock warrant liability	-2	233
Loss on sale or disposal of equipment	401	30
Changes in operating assets and liabilities:	'	'
Accounts receivable, net	-1,362	-2,431
Inventories	-87	0
Prepaid expenses and other	-59	-126
Accounts payable, accrued expenses and other current liabilities	-462	229
Other non-current assets	-31	0
Other long-term liabilities	146	1,585
Net cash (used in) provided by operating activities	-9,007	2,408
Investing activities	'	'
Purchases of property and equipment	-2,939	-5,727
Capitalized patent and trademark costs	-154	-74
Proceeds from sale of equipment	150	0
Net cash used in investing activities	-2,943	-5,801
Financing activities	'	'
Payments on revolving line of credit	-5,000	0
Payments of Series F redeemable convertible preferred stock accrued dividends	-5,200	0
Payments on long-term debt	0	-1,600
Changes in restricted cash for operating lease	1,004	-1
Changes in deferred financing costs	-6	0
Deferred offering costs	0	-748
Issuance cost of common stock	-4,443	0
Proceeds from line of credit	0	3,500
Proceeds from issuance of common stock	51,750	0
Proceeds from exercise of stock options and warrants	651	38
Net cash provided by financing activities	38,756	1,189
Net increase (decrease) in cash and cash equivalents	26,806	-2,204
Cash and cash equivalents at beginning of period	24,768	12,483
Cash and cash equivalents at end of period	51,574	10,279
Supplemental disclosure of cash flow information	'	'
Cash paid for interest	1,092	330
Supplemental disclosure of noncash investing activities	'	'
Fixed asset expenditures included in accounts payable and accrued expenses	$612	$411

Description_of_Business_and_Si

Description of Business and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Description of Business and Significant Accounting Policies	'
	Description of Business and Significant Accounting Policies
	Description of Business
	LipoScience, Inc. (“LipoScience” or the “Company”) was incorporated under the laws of North Carolina in June 1994 under the name LipoMed, Inc. and reincorporated under the laws of Delaware in June 2000. In January 2002, the Company changed its corporate name to LipoScience, Inc. The Company is an in vitro diagnostic company pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (“NMR”) technology. The Company's first diagnostic test, the NMR LipoProfile test, is cleared by the U.S. Food and Drug Administration (the "FDA"), and directly measures the number of low density lipoprotein, (“LDL”) particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease.
	Basis of Presentation and Use of Estimates
	The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include all adjustments necessary for the fair presentation of the Company's financial position, results of operations and cash flows for the periods presented. In preparing the financial statements, management must make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates and assumptions used.
	Unaudited Financial Statements
	The accompanying unaudited financial statements have been prepared in accordance with the rules and regulations for the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete annual financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2012 contained in the Company's Annual Report on Form 10-K filed with the SEC on March 27, 2013 (the "Form 10-K"). The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company's financial position as of September 30, 2013, the results of operations for the three and nine months ended September 30, 2013 and 2012, and cash flows for the nine months ended September 30, 2013 and 2012. The December 31, 2012 balance sheet included herein was derived from audited financial statements, but does not include all disclosures including notes required by GAAP for complete annual financial statements. The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September 30, 2013 and 2012 are unaudited. Interim results are not necessarily indicative of results to be expected for the year ending December 31, 2013 or any other interim period or for any other future year.
	Reverse Stock Split
	On January 4, 2013, the Company's Board of Directors approved a 0.485-for-1 reverse stock split of the Company's outstanding common stock. The reverse stock split was effected on January 10, 2013, which resulted in an adjustment to the preferred stock conversion price to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying financial statements and notes to financial statements give retroactive effect to the reverse stock split for all periods presented.
	Initial Public Offering
	On January 30, 2013, the Company closed its initial public offering ("IPO") pursuant to a registration statement that was declared effective on January 24, 2013. The Company sold 5,750,000 shares of its common stock in the IPO, at a price to the public of $9.00 per share, for aggregate gross proceeds of $51.8 million, which included 750,000 shares of its common stock that the underwriters purchased pursuant to an over-allotment option granted to the underwriters. As a result of the IPO, the Company raised a total of $44.4 million in net proceeds after deducting underwriting discounts and commissions of $3.4 million and offering costs of $4.0 million. Costs directly associated with the IPO were capitalized and recorded as deferred offering costs prior to the closing of the IPO. These costs were recorded as a reduction of the IPO proceeds received in arriving at the amount to be recorded in additional paid-in capital. Upon the closing of the IPO, 12,892,682 shares of the Company's outstanding preferred stock automatically converted into a total of 6,994,559 shares of its common stock, and the then-outstanding preferred stock warrant liability was reclassified to additional paid-in capital upon the conversion of warrants to purchase preferred stock into warrants to purchase common stock.
	Concurrently with the closing of the IPO, the Company paid $5.2 million to holders of its Series F redeemable convertible preferred stock in full satisfaction of accrued dividends on such shares immediately prior to their conversion to common stock.
	Customers and Payors
	The Company provides diagnostic tests to a broad range of customers. A majority of these tests are comprised of orders generated through clinical diagnostic laboratory customers and clinicians. The Company also receives requests from academic institutions as well as pharmaceutical companies. In most cases, the customer that orders the tests is not responsible for the payments for services. The Company considers a party that refers a test to it to be a “customer” and a party that reimburses the Company as a “payor.” Depending on the billing arrangement and applicable law, the payor may be (i) a clinical diagnostic laboratory, (ii) a third party responsible for providing health insurance coverage to patients, such as a health insurance plan or the traditional Medicare or Medicaid program, (iii) the physician or (iv) the patient or other party (such as academic institutions or pharmaceutical companies) who requested the test from the Company.
	Revenue Recognition
	The Company currently derives revenue from sales of its NMR LipoProfile test to clinical diagnostic laboratories and clinicians for use in patient care, from sales of ancillary tests for use in patient care requested in conjunction with the NMR LipoProfile test and from contract research arrangements.
	Revenues from diagnostic tests for patient care, which consist of sales of the NMR LipoProfile test performed at the Company's laboratory facility and at third party clinical diagnostic laboratory facilities (see “The Vantera System Placement Arrangements” below) and sales of ancillary tests, are recognized on the accrual basis when the following revenue recognition criteria are met: (1) persuasive evidence that an arrangement exists; (2) services have been rendered or at the time final results are reported; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Testing services provided for patient care are covered by clinical diagnostic laboratories through negotiated contracts with commercial insurance carriers, programs with commercial insurance carriers (including managed care organizations) and various governmental programs, primarily Medicare.
	Billings for diagnostic tests for patient care under governmental and physician-based programs are included in revenues net of contractual adjustments. These contractual adjustments represent the difference between the final settlement amount paid by the program and the estimated settlement amount based on either the list price for tests performed or the reimbursement rate set by commercial insurance carriers or governmental programs. Estimated contractual adjustments are updated either upon notification from payors as to changes in existing reimbursement rates, which are typically received prior to changes going into effect, or upon a material variance between the final settlement and the estimated contractual adjustment originally established when the revenues were recognized. To date, the Company's final settlement adjustments have not been material.
	Revenues from contract research arrangements are generally derived from studies conducted by academic institutions and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given agreement. The Company's output, measured in terms of full-time equivalent level of effort or processing a set of diagnostic tests under a contractual protocol, typically triggers payment obligations under these agreements. Revenues are recognized as costs are incurred or diagnostic tests are processed. Contract research costs include all direct material and labor costs, equipment costs and fringe benefits. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met.
	Billing for diagnostic testing services for patient care is complex. In most cases, tests are performed in advance of payment and without certainty as to the outcome of the billing process, which may negatively affect revenues, cash flow and profitability. Payments are received from a variety of payors, including clinical diagnostic laboratories, commercial insurance carriers (including managed care organizations), governmental payors (primarily Medicare) and individual patients. Each payor typically has different billing requirements, and the billing requirements of many payors have become increasingly stringent.
	The Company generally assumes the financial risk related to collection, including the potential uncollectibility of accounts and the other complex factors identified above. For sales of its NMR LipoProfile test to clinical diagnostic laboratories, the clinical diagnostic laboratories are responsible for obtaining reimbursement from third-party payors or directly from patients. Delays in collection and uncollectible bills may negatively affect the Company's revenues, cash flow and profitability.
	The Vantera System Placement Arrangements
	The Company's automated clinical analyzer, the Vantera system, was cleared by the FDA in August 2012 and became commercially available in December 2012. The Company started placing the Vantera system on-site with certain qualified national and regional clinical diagnostic laboratories as well as leading medical centers and hospital outreach laboratories during the second quarter of 2013.
	The Company's Vantera system placement arrangements (or “placement arrangements”) are generally negotiated and accounted for as operating leases. Arrangement consideration is determined based on the test volume and the negotiated price-per-reportable NMR LipoProfile test result. The placement arrangements typically include lease and non-lease deliverables. Lease deliverables include the right to use the Vantera system and related maintenance and support, while non-lease deliverables consist of the NMR LipoProfile test and consumables. Lease deliverables are accounted for in accordance with specific leasing guidance while non-lease deliverables are accounted for in accordance with the multiple-element arrangement guidance.
	The Company evaluates each non-lease deliverable to determine whether it represents a separate unit of accounting. A deliverable is considered a separate unit of accounting when the delivered item has stand-alone value and delivery of the undelivered element is probable and within the Company's control. The Company has determined that both the NMR LipoProfile test and consumables have separate units of accounting. The NMR LipoProfile test is the Company's most significant deliverable under these placement arrangements.
	The Company allocates revenue to each deliverable at the inception of the placement arrangement, based on its estimated stand-alone value in relation to the combined estimated stand-alone value of all deliverables, or the relative selling price method. Revenue allocated to each deliverable is then recognized when the basic revenue recognition criteria, as described above, is met for each deliverable.
	The Company applies the following selling price hierarchy in determining the selling price for each deliverable:
	•	Vendor-specific objective evidence (“VSOE”) if available-the price charged for a deliverable when it is sold separately and, in other instances, using the price established by management having the relevant authority.
	•	Third-party evidence (“TPE”) if VSOE is not available-the price of the vendor's or any competitor's largely interchangeable products or services in standalone sales to similarly situated customers.
	•	Estimated selling price (“ESP”) if neither VSOE or TPE is available-the price best estimated by the vendor and at which the vendor would transact if the deliverable would have been sold by the vendor regularly on a standalone basis.
	The Company has determined that only the selling price of its NMR LipoProfile test is based on VSOE. The Company does not sell the license to use the Vantera system, the consumables or related maintenance and support separately on a regular basis and therefore it does not have the evidence to support VSOE for these deliverables. Due to the high degree of customization involved with these deliverables, the Company has determined that there is no comparable TPE for these deliverables. Since these deliverables have neither VSOE nor TPE, the allocation of revenue to them has been based on the Company's ESP.
	The Company's process for determining ESP for its deliverables considers all reasonably available information including both market data and conditions, as well as entity specific factors that may vary depending upon the facts and circumstances related to each deliverable. Key factors considered in developing ESP relating to deliverables include cost structures, established pricing and approval policies and customization of the product or service and industry pricing. The Company regularly reviews ESP and maintains internal controls over the establishment and updates of these estimates.
	Shipping and Handling
	The Company does not bill its customers for shipping and handling charges. All charges relating to inbound and outbound freight costs are incurred by the Company and recorded within cost of revenues. The Company incurred shipping and handling costs of $0.2 million and $0.4 million for the three months ended September 30, 2013 and 2012, respectively, and $1.0 million and $1.2 million for the nine months ended September 30, 2013 and 2012, respectively.
	Fair Value of Financial Instruments
	The Company measures certain financial assets and liabilities at fair value based on the price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. As of September 30, 2013 and December 31, 2012, the Company's financial instruments consisted principally of cash and cash equivalents, a revolving line of credit, long-term debt and preferred stock warrant liability. See Note 2, “Fair Value Measurement,” to the financial statements for further information on the fair value of the Company's financial instruments.
	Cash and Cash Equivalents
	The Company invests its available cash balances in cash, certificates of deposits and money market funds. The Company considers all highly liquid instruments purchased with original maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents are stated at cost and the carrying amounts approximate fair value. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity. See Note 6 for a discussion of Restricted Cash.
	Accounts Receivable
	Accounts receivable are primarily amounts due from clinical diagnostic laboratories, commercial insurance companies (including managed care organizations), governmental programs (primarily Medicare), physicians, and individual patients.
	Accounts receivable are reported net of an allowance for uncollectible accounts and contractual allowance adjustments. The process of estimating the collection of accounts receivable involves significant assumptions and judgments. Specifically, the accounts receivable allowance is based on management's analysis of current and past due accounts, collection experience in relation to amounts billed, changes in reimbursement levels, known contract terms, channel mix, any specific customer collection issues that have been identified and other relevant information. The Company's provision for uncollectible accounts is recorded as bad debt expense and included in general and administrative expenses. Historically, the Company has not experienced significant credit loss related to its customers or payors. Although the Company believes amounts provided are adequate, the ultimate amounts of uncollectible accounts receivable could be in excess of the amounts provided.
	Inventories
	Inventories consist of materials and spare parts to service the Vantera system. Inventories are valued at the lower of cost or net realizable value. The cost of inventories is maintained using the average-cost method.
	Property and Equipment
	Property and equipment are stated at cost. Property and equipment financed under capital leases are initially recorded at the present value of minimum lease payments at the inception of the lease. Amortization of assets financed under capital leases is included with purchased property and equipment as part of depreciation and amortization.
	Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Property and equipment under capital leases and leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life of the asset. Depreciable lives range from three to seven years for laboratory equipment, customer-use assets, office equipment and furniture and fixtures and three years for software.
	Intangible Assets
	Intangible assets include patent costs, trademark costs and technology licenses that are capitalized and amortized over estimated useful lives (generally nine to twenty years) using the straight-line method. Patent costs are expensed if the patent is not granted. On an ongoing basis, the Company assesses the recoverability of its intangible assets by determining its ability to generate undiscounted future cash flows sufficient to recover the unamortized balances over the remaining useful lives. Intangible assets determined to be unrecoverable are expensed in the period in which the determination is made.
	Amortization expense on intangible assets was $6,000 and $4,000 for the three months ended September 30, 2013 and 2012, respectively, and $17,000 and $14,000 for the nine months ended September 30, 2013 and 2012, respectively.
	Impairment of Long-Lived Assets
	The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may be impaired and assesses their recoverability based upon anticipated future cash flows. If changes in circumstances lead the Company to believe that any of its long-lived assets may be impaired, the Company will (a) evaluate the extent to which the remaining book value of the asset is recoverable by comparing the future undiscounted cash flows estimated to be associated with the asset to the asset's carrying amount and (b) write-down the carrying amount to market value or discounted cash flow value to the extent necessary.
	Deferred Offering Costs
	Deferred offering costs represent legal, accounting and other direct costs related to the Company's efforts to raise capital through the IPO. Costs related to the Company's IPO activities were deferred until the completion of the IPO, at which time they were reclassified to additional paid-in capital as a reduction of the IPO proceeds. Upon closing of the IPO, the $3.2 million of deferred offering costs at December 31, 2012 were recorded as a reduction of the proceeds received.
	Redeemable Convertible Preferred Stock
	The Company had historically classified its redeemable convertible preferred stock, for which the Company did not control the redemption, outside of permanent equity. The Company had recorded redeemable convertible preferred stock at fair value upon issuance, net of any issuance costs or discounts, and the carrying value was increased by periodic accretion to its redemption value. These increases were effected through charges against additional paid-in capital. Upon closing of the IPO, all outstanding redeemable convertible preferred stock as well as convertible preferred stock was reclassified to additional paid-in capital. The notes to the Company's audited financial statements for the year ended December 31, 2012 included in its Annual Report on Form 10-K for that year, filed with the Securities and Exchange Commission on March 27, 2013, provide details regarding the various features of the redeemable convertible preferred stock.
	Preferred Stock Warrant Liability
	The Company had historically accounted for its freestanding warrants to purchase the Company's Series E and Series F Redeemable Convertible Preferred Stock as liabilities at fair value on the accompanying balance sheets. The warrants were subject to re-measurement at each balance sheet date, and the change in fair value, if any, was recognized as other income or expense. As a result of the IPO, all preferred stock warrant liability was reclassified to additional paid-in capital upon the conversion of warrants to purchase preferred stock into warrants to purchase common stock.
	Concentration of Credit Risk and Other Risks
	The Company derives its revenues from diagnostic testing services provided for patient care and contract research arrangements with institutional customers. The Company operates in one industry segment. Substantially all of the Company's historical revenues have been derived from the sale of the NMR LipoProfile test.
	The Company's principal financial instruments subject to potential concentration of credit risk are cash equivalents and trade accounts receivable, which are unsecured. Through September 30, 2013, no material losses have been incurred.
	Revenues from customers representing 10% or more of total revenues for the respective periods, are summarized as follows:
		Three Months Ended September 30,				Nine Months Ended September 30,
		2013		2012		2013		2012
Health Diagnostics Laboratory	33	%	34	%	34	%	32	%
LabCorp	30		29		30		29
The Company’s accounts receivable due from these significant customers as a percentage of total accounts receivable was as follows as of the dates indicated:
	September 30, 2013		December 31, 2012
Health Diagnostics Laboratory	37	%	*
LabCorp	19		39	%
* Less than 10%.
The Company depends on a limited number of suppliers, including single-source suppliers, of various critical components used in its Vantera system and existing NMR clinical analyzers. The loss of these suppliers, or their failure to supply the Company with the necessary components on a timely basis, could cause delays in the placement of Vantera system or the diagnostic testing process and adversely affect the Company.
Research and Development Expenses
Research and development expenses include all costs associated with the development of NMR technology products and are charged to expense as incurred. Research and development expenses include direct costs and an allocation of indirect costs, including amortization, depreciation, telephone, rent, supplies, insurance and repairs and maintenance.
Financing Costs
The Company capitalizes direct financing costs, which are included as other noncurrent assets on the Company's balance sheets. The Company accretes debt discounts, which are included as a direct deduction from the face amount of the financing. Debt financing costs and debt discounts are deferred and amortized to interest expense using the effective interest method over the life of the related debt. The related expense is included in interest expense in the Company's statements of comprehensive (loss) income.
Income Taxes
The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company's assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.
The Company has adopted the accounting guidance for uncertainties in income taxes, which proscribes a recognition threshold and measurement process for recording uncertain tax positions taken, or expected to be taken, in a tax return in the financial statements. Additionally, the guidance also proscribes a new treatment for the derecognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. The Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained. As of the date of adoption of this guidance, the Company did not have any accrued interest or penalties associated with any unrecognized tax positions, and there were no such interest or penalties recognized during the three and nine months ended September 30, 2013 and 2012.
Advertising
Advertising costs, which are included in sales and marketing expenses, are expensed as incurred. Advertising expense was $0.2 million and $0.4 million for the three months ended September 30, 2013 and 2012, respectively, and $0.7 million for each of the nine months ended September 30, 2013 and 2012.
Stock-Based Compensation
The Company accounts for stock-based compensation arrangements with employees and non-employee directors using a fair value method that requires the recognition of compensation expense for costs related to all stock-based payments, including stock options and restricted stock units. The fair value method requires the Company to estimate the fair value of stock options on the date of grant using an option pricing model. The fair value of restricted stock units is estimated based on the closing price of the Company's stock on the date of grant, and for the purposes of expense recognition, the total new number of shares expected to vest is adjusted for estimated forfeitures.
Stock-based compensation costs for stock options are based on the fair value of the underlying option calculated using the Black-Scholes option-pricing model on the date of grant for stock options and recognized as expense on a straight-line basis over the requisite service period, which is the vesting period. Determining the appropriate fair value model and related assumptions requires judgment, including estimating stock price volatility, forfeiture rates and expected term. The expected volatility rates are estimated based on the actual volatility of comparable public companies over the expected term. The expected term represents the average time that options are expected to be outstanding based on the mid-point between the vesting date and the end of the contractual term of the award. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has not paid dividends and does not anticipate paying a cash dividend in the foreseeable future and, accordingly, uses an expected dividend yield of zero. The risk-free interest rate is based on the rate of U.S. Treasury securities with maturities consistent with the estimated expected term of the awards. The measurement of nonemployee share-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the period over which services are received.
Segment Reporting
The Company operates in one operating segment. The Company's chief operating decision maker (the “CODM”), currently its interim chief executive officer, manages the Company's operations on an integrated basis for purposes of allocating resources. When evaluating the Company's financial performance, the CODM reviews separate revenue information for the Company's patient care testing and its research services, while all other financial information is reviewed on a combined basis. All of the Company's principal operations and decision-making functions are located in the United States. Accordingly, the Company has determined that it has a single reporting segment.
Off-Balance Sheet Arrangements
Through September 30, 2013, the Company has not entered into any off-balance sheet arrangements, other than the operating leases described in Note 14, and does not have any holdings in variable interest entities.
Recent Accounting Pronouncements
In October 2012, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2012-04, Technical Corrections and Improvements. The amendments in this update cover a wide range of topics in the Accounting Standards Codification. These amendments include technical corrections and improvements to the Accounting Standards Codification and conforming amendments related to fair value measurements. For public companies, the amendments that are subject to the transition guidance were effective for reporting periods beginning after December 15, 2012. Accordingly, the Company adopted this update on January 1, 2013. Adoption of this new guidance had no material impact on the Company's financial statements.
In February 2013, the FASB issued ASU No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. The amendments in this update are intended to improve the reporting of reclassifications out of accumulated other comprehensive income by requiring an entity to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required to be reclassified in its entirety to net income. For other amounts that are not required to be reclassified in their entirety to net income in the same reporting period, an entity is required to cross-reference other disclosures required that provide additional detail about those amounts. This would be the case when a portion of the amount reclassified out of accumulated other comprehensive income is reclassified to a balance sheet account instead of directly to income or expense in the same reporting period.   For public companies, the amendments that are subject to this update were effective for interim and annual reporting periods beginning after December 15, 2012. Accordingly, the Company adopted this update on January 1, 2013. Adoption of this new guidance had no material impact on the Company's financial statements.
In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. The amendments in this update provide clarification, and are intended to reduce diversity in practice, on the financial statement presentation of unrecognized tax benefits. The guidance specifies that an unrecognized tax benefit (or a portion thereof) shall be presented in the financial statements as a reduction to a deferred tax asset when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. If such deferred tax asset is not available at the reporting date to settle additional income taxes resulting from the disallowance of a tax position, or the entity does not plan to use the deferred tax asset for such purpose given the option, the unrecognized tax benefit shall be presented in the financial statements as a liability and shall not be combined with deferred tax assets. The assessment of whether a deferred tax asset is available is based on the unrecognized tax benefit and deferred tax asset that exist at the reporting date and should be made presuming disallowance of the tax position at the reporting date. For public companies, the amendments that are subject to this update are effective for interim and annual reporting periods beginning after December 15, 2013, with early adoption permitted. The Company’s current practice is consistent with the amendments in this update. The Company expects that the new guidance will have no material impact on the Company’s financial statements.

Fair_Value_Measurement

Fair Value Measurement	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurement	'
	Fair Value Measurement
	As a basis for determining the fair value of certain of the Company's financial instruments, the Company utilizes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	•	Level I - Observable inputs such as quoted prices in active markets for identical assets or liabilities.
	•	Level II - Observable inputs, other than Level I prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	•	Level III - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company did not elect to report any of its non-financial assets or non-financial liabilities at fair value.
	The fair value of the Company's revolving line of credit and long-term debt were estimated using the discounted cash flow method, which is based on the future expected cash flows, discounted to their present values, using a discount rate that approximates market rates. The carrying value of the Company's revolving line of credit and long-term debt as of September 30, 2013 and December 31, 2012 approximated fair value because the interest rates under those obligations approximate market rates of interest available to the Company for similar instruments.
	Recurring Fair Value Measurements
	The Company's financial instruments that are measured at fair value on a recurring basis consist only of cash equivalents and the preferred stock warrant liability prior to the completion of the IPO. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability.
	Cash equivalents
	All of the Company's cash equivalents, which include certificates of deposits and money market funds, are classified within Level I of the fair value hierarchy because they are valued using quoted market prices.
	Preferred stock warrant liability
	The fair value determination of the Company's preferred stock warrant liability had historically required a number of assumptions, including significant unobservable inputs that reflect the Company's own assumptions about the assumptions a market participant would use in valuing the liability, and therefore was classified within Level III of the fair value hierarchy. The significant unobservable inputs used in the fair value measurement of the Company's preferred stock warrant liability were (i) probability weighting of potential liquidity event outcomes, (ii) the implied value of the underlying preferred shares derived in the IPO scenario and (iii) the weighted average cost of capital (“WACC”). Significant increases (decreases) in the probability weighting of potential liquidity event outcomes and the implied value of the underlying preferred stock in isolation would historically resulted in a significantly higher (lower) fair value measurement. Conversely, significant increases (decreases) in the anticipated timing of a liquidity event and WACC inputs in isolation would historically resulted in a significantly lower (higher) fair value measurement.
	The following table sets forth the Company's financial instruments that were measured at fair value as of September 30, 2013 and December 31, 2012 by level within the fair value hierarchy (in thousands):
		September 30, 2013							December 31, 2012
		Level I			Level III		Total		Level I		Level III		Total
	Assets
	Certificates of deposits	$	—		$	—	$	—	$	5,253	$	—	$	5,253
	Money market funds	502			—		502		21,016		—		21,016
	Total assets measured at fair value	$	502		$	—	$	502	$	26,269	$	—	$	26,269
	Liabilities
	Preferred stock warrant liability	$	—		$	—	$	—	$	—	$	412	$	412
	Total liabilities measured	$	—		$	—	$	—	$	—	$	412	$	412
	at fair value
	The change in the fair value of the Level III preferred stock warrant liability is summarized below (in thousands):
		Nine Months Ended September 30,
		2013			2012
	Fair value at beginning of period	$	412		$	229
	Reclassification to additional paid in capital upon the IPO	(410		)	—
	Change in fair value recorded in other expense	(2		)	233
	Fair value at end of period	$	—		$	462
	For the nine months ended September 30, 2013, there were no transfers between Level I and Level II within the fair value hierarchy.

Cash_and_Cash_Equivalents

Cash and Cash Equivalents	9 Months Ended
	Sep. 30, 2013
Cash and Cash Equivalents [Abstract]	'
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	Cash and cash equivalents consist of the following as of (in thousands):
		September 30, 2013		December 31, 2012
	Cash	$	51,574	$	4
	Certificates of deposit	—		5,253
	Money market funds	—		19,511
	Total cash and cash equivalents	$	51,574	$	24,768
	The Company has an arrangement with its primary bank that excess cash balances are transferred daily to an overnight sweep deposits account. At September 30, 2013, the balance in the overnight sweep deposits account totaling $4.5 million was invested in bank deposits which are classified as cash on the Company's balance sheet. At December 31, 2012, the balance in the overnight sweep deposits account totaling $19.5 million was invested in shares of a money market fund.

Accounts_Receivable_and_Revenu

Accounts Receivable and Revenues	9 Months Ended
	Sep. 30, 2013
Receivables [Abstract]	'
Accounts Receivable and Revenues	'
	Accounts Receivable and Revenues
	Accounts receivable, net, consists of the following as of (in thousands):
		September 30, 2013			December 31, 2012
	Accounts receivable	$	7,617		$	6,526
	Less allowance for uncollectible accounts receivable	(1,106		)	(1,377		)
	Accounts receivable, net	$	6,511		$	5,149
	Activity for the allowance for uncollectible accounts receivable is as follows (in thousands):
		Nine Months Ended September 30, 2013			Year Ended December 31, 2012
	Balance at beginning of period	$	1,377		$	1,676
	Provision for bad debt expense	212			818
	Write-off, net of recoveries	(483		)	(1,117		)
	Balance at end of period	$	1,106		$	1,377
	Revenues consist of the following (in thousands):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013			2012
	Gross billings	$	13,112		$	13,985		$	40,711		$	42,692
	Less contractual adjustments	(374		)	(421		)	(1,046		)	(1,451		)
	Revenues	$	12,738		$	13,564		$	39,665		$	41,241

Property_and_Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	Property and Equipment
	Property and equipment consists of the following as of (in thousands):
		September 30, 2013			December 31, 2012
	Laboratory equipment	$	9,605		$	9,415
	Office equipment, furniture and fixtures	3,416			3,497
	Leasehold improvements	3,229			2,652
	Software	2,154			1,793
	Customer-use assets	328			—
	Construction in progress	6,167			5,778
		24,899			23,135
	Less accumulated depreciation	(12,319		)	(11,642		)
	Property and equipment, net	$	12,580		$	11,493
	Customer-use assets represent the Company's Vantera system placed at customer sites, to which title and risk of loss is retained by the Company, for the customer's use in performing the NMR LipoProfile tests sold by the Company.
	Depreciation expense was $0.4 million and $0.3 million for the three months ended September 30, 2013 and 2012, respectively, and was $1.2 million and $0.9 million for the nine months ended September 30, 2013 and 2012, respectively.
	During the three and nine months ended September 30, 2013, the Company recognized a $0.4 million loss on sale of assets, measured at fair value less cost to sell, in connection with the sale of a Vantera system to a medical research center for research and development purposes. This loss on sale of assets is recorded as research and development expense within the statement of comprehensive (loss) income. Additionally, the Company retired $0.3 million and $0.5 million of fully depreciated assets during the three and nine months ended September 30, 2013, respectively. The Company disposed of $30,000 of damaged assets during the nine months ended September 30, 2012, and during the three and nine months ended September 30, 2012, the Company retired $0.9 million of fully depreciated assets.

Restricted_Cash

Restricted Cash	9 Months Ended
	Sep. 30, 2013
Restricted Cash and Investments [Abstract]	'
Restricted Cash	'
	Restricted Cash
	As of September 30, 2013 and December 31, 2012, money market funds totaling $0.5 million and $1.5 million, respectively, were pledged as security for the Company's office and laboratory space operating lease. These funds may be released by the bank upon the achievement of minimum sales and cash flow levels and upon the satisfaction of specified financial ratios.

Accrued_Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Accrued Expenses	'
	Accrued Expenses
	Accrued expenses consist of the following as of (in thousands):
		September 30, 2013		December 31, 2012
	Accrued wages and benefits	$	2,072	$	1,541
	Accrued bonus	528		2,200
	Other accrued liabilities	1,220		1,608
	Total accrued expenses	$	3,820	$	5,349

LongTerm_Debt_and_Line_of_Cred

Long-Term Debt and Line of Credit	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Long-Term Debt and Line of Credit	'
	Long-Term Debt and Line of Credit
	The Company had total debt with a carrying value of $15.8 million and $15.7 million as of September 30, 2013 and December 31, 2012, respectively. Long-term debt consists of the following (in thousands):
		September 30, 2013			December 31, 2012
	Long-term debt to financial institutions	$	16,000		$	16,000
	Less unamortized debt discount	(212		)	(292		)
	Less current maturities of long-term debt	(3,904		)	—
	Long-term debt, less current maturities and unamortized debt discount	$	11,884		$	15,708
	Credit Facility
	On December 20, 2012, the Company entered into a credit facility with Square 1 and Oxford Finance and repaid the outstanding balance under a previous facility. The current credit facility consists of $16.0 million in term loans and a revolving line of credit of up to $6.0 million in borrowing capacity, subject to certain limitations relating to the Company's eligible accounts receivable. In connection with entering into the current credit facility, the Company issued warrants to these financial institutions to purchase an aggregate of 73,564 shares of Series E redeemable convertible preferred stock at an exercise price of $4.35 per share. The Company determined the fair value of the warrants at issuance to be $0.2 million. In connection with the IPO, the warrants converted into warrants to purchase common stock (see Note 10, "Preferred Stock Warrant Liability"). At September 30, 2013, total unamortized debt issuance costs incurred in connection with the current credit facility were $74,000.
	The term loans carry interest at a fixed annual rate of 9.5% and are payable in monthly installments of interest only through January 2014 and then principal and interest thereafter in monthly installments through July 2016. Advances under the revolving line of credit, which matures in December 2013, carry a variable interest rate equal to the greater of 6.25% or the institution's prime rate plus 3.0%.
	As of December 31, 2012, the Company had borrowed $5.0 million under the revolving line of credit. During the three months ended March 31, 2013, the Company paid off outstanding balances under the revolving line of credit and there was no amount outstanding as of September 30, 2013.
	Borrowings under the credit facility are secured by substantially all of the Company's tangible assets. The covenants set forth in the loan and security agreement require, among other things, that the Company maintain a specified liquidity ratio, measured monthly, that begins at 1.25 and is reduced to 1.0 over the term of the credit facility. The Company is also required to achieve minimum three-month trailing revenue levels relative to projections approved by the Company's Board of Directors, and beginning in 2014 such three-month trailing revenue levels must also be equal to or greater than the revenues for the same period for the prior year.
	In June 2013, the Company discovered that it had failed to comply with the covenant set forth in the loan agreement related to minimum three-month trailing revenue levels against prior period for the measuring periods from March 2013 to May 2013. On June 11, 2013, the Company entered into a first amendment to the loan agreement to waive the noncompliance with this covenant for the measuring periods described above, and to eliminate the necessity of complying with this financial covenant through the end of 2013. As of September 30, 2013 and December 31, 2012, the Company was in compliance with all financial and non-financial covenants under this credit facility, as modified.

Net_Loss_Income_Per_Share

Net (Loss) Income Per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Net (Loss) Income Per Share	'
	Net (Loss) Income Per Share
	Net (Loss) Income Per Share
	The Company computes basic net (loss) income per share by dividing net (loss) income by the weighted average number of shares of common stock outstanding for the period, without consideration for common share equivalents. Diluted net (loss) income per share is computed on the basis of the weighted average number of shares of common stock plus dilutive potential common share equivalents during the period, consisting of incremental common shares deemed outstanding from the assumed exercise of common stock options, warrants and restricted stock units. The dilutive effect of common share equivalents is reflected in diluted earnings per shares by application of treasury stock method. Under the treasury stock method, earnings per share data is computed as if the common share equivalents were outstanding at the beginning of the period (or at the time of issuance, if later) and as if the funds obtained from exercise of the common share equivalents were used to purchase common stock at the average market price during the period.
	Prior to the IPO, the Company computed net (loss) income per share in accordance with the accounting guidance regarding the computation of earnings or net loss per share by companies that have issued securities other than common stock that contractually entitle the holder to participate in earnings and dividends. Basic net (loss) income per share was computed by dividing net (loss) income allocable to common stockholders, which was net (loss) income after deduction of any required returns to preferred stockholders prior to paying dividends to the common stock and assuming current income for the period had been distributed based on the respective rights of the common and preferred stockholders to receive dividends, by the weighted average number of shares of common stock outstanding during the period. Diluted net (loss) income per share was computed on the basis of the weighted average number of shares of common stock plus dilutive potential common shares outstanding during the period. Since the Company's participating preferred stock was not contractually required to share in the Company's losses, in applying the two-class method to compute basic net (loss) income per share, no allocation was made to preferred stock if a net loss existed.
	Because of their anti-dilutive effect, the following common stock equivalents, consisting of convertible preferred shares, redeemable convertible preferred shares, common stock options, warrants and restricted stock units, have been excluded from the diluted loss per share calculations for the respective periods presented:
		Three Months Ended September 30,						Nine Months Ended September 30,
	Anti-Dilutive Common Share Equivalents:	2013			2012			2013		2012
	Convertible Preferred Stock (Series A, A-1, B, B-1, C, and C-1)	—			1,222,211			—		1,222,211
	Redeemable Convertible Preferred Stock (Series D, D-1, E and F)	—			5,763,606			—		5,763,606
	Common Stock Options and Warrants	2,171,715			2,445,633			2,171,715		327,579
	Restricted Stock Units	112,592			—			112,592		—
		2,284,307			9,431,450			2,284,307		7,313,396
	A reconciliation of the numerator and denominator used in the computation of basic and diluted net (loss) income per share allocable to common stockholders follows (in thousands, except share and per share data):
		Three Months Ended September 30,							Nine Months Ended September 30,
		2013				2012			2013			2012
	Historical net (loss) income per share:
	Numerator:
	Net (loss) income	$	(4,627	)		$	(481	)	$	(9,919	)	$	1,057
	Less: Undistributed earnings allocated to participating preferred shares	—				—			—			(850		)
	Net (loss) income attributable to common stockholders – basic	(4,627		)		(481		)	(9,919		)	207
	Add: Undistributed earnings re-allocated to common stockholders	—				—			—			122
	Net (loss) income attributable to common stockholders – diluted	$	(4,627	)		$	(481	)	$	(9,919	)	$	329
	Denominator:
	Weighted average common shares outstanding – basic	14,727,286				1,704,689			14,727,286			1,704,689
	Dilutive effect of common stock equivalent shares resulting from common stock options and warrants	—				—			—			1,446,413
	Weighted average common shares outstanding – diluted	14,727,286				1,704,689			14,727,286			3,151,102
	Net (loss) income per common share:
	Net (loss) income per share attributable to common stockholders – basic	$	(0.31	)		$	(0.28	)	$	(0.67	)	$	0.12
	Net (loss) income per share attributable to common stockholders – diluted	$	(0.31	)		$	(0.28	)	$	(0.67	)	$	0.1

Equity_Transactions_and_ShareB

Equity Transactions and Share-Based Compensation	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Equity Transactions and Share-Based Compensation	'
	Equity Transactions and Share-Based Compensation
	Preferred Stock Warrant Liability
	Prior to the IPO, the Company accounted for its freestanding warrants to purchase the Company's Series E and Series F Redeemable Convertible Preferred Stock as liabilities at fair value on its balance sheets. The warrants were subject to re-measurement at each balance sheet date, and the change in fair value, if any, was recognized as other expense. The Company estimated the fair value of these warrants at the respective balance sheet dates using the Black-Scholes option pricing model. The estimated fair value of the Company, calculated at each valuation date, was allocated to the shares of redeemable convertible preferred stock, convertible preferred stock, warrants to purchase shares of redeemable convertible preferred stock, and common stock, using a “hybrid” approach of the probability-weighted expected return method and the option pricing model. This approach treats the various components of the Company's capital structure as a series of call options on the proceeds expected from the sale of the Company or the liquidation of the Company's assets in the future. This approach defines the securities' fair values as functions of the current fair value of the Company and assumptions based on the securities' rights and preferences. These call options were then valued using the Black-Scholes option pricing model. As a result, the option-pricing model requires a number of assumptions to estimate the fair value including the anticipated timing of a potential liquidity event, such as an initial public offering, remaining contractual terms of the warrant, risk-free interest rates, expected dividend yield and the estimated volatility of the price of the underlying securities. The anticipated timing of a liquidity event utilized in these valuations was based on then current plans and estimates of the Company's board of directors and management regarding the IPO. These assumptions were highly judgmental.
	The fair values of outstanding Series E and Series F Redeemable Convertible Preferred Stock warrants were estimated using the Black-Scholes option-pricing model with the following assumptions as of:
			December 31, 2012
	Expected term (in years)		0.25-0.5
	Risk-free interest rate		0.0%-0.1%
	Expected volatility		30	%
	Expected dividend rate		0	%
	The Company adjusted the liability for changes in fair value until the earlier of (i) exercise of the warrants, (ii) conversion of the warrants into warrants to purchase common stock upon an event such as the completion of the IPO or (iii) expiration of the warrants. Upon the completion of the IPO in January 2013, all warrants to purchase redeemable convertible preferred stock were converted into warrants to purchase common stock, and the preferred stock warrant liability was reclassified into additional paid-in capital at its then fair value of $0.4 million.
	Common Stock Warrants
	As of September 30, 2013, the following warrants to purchase common stock were outstanding:
	Issuance Date			Number of Shares			Exercise Price			Expiration Date
	12/13/06			6,689			$	8.97		12/13/13
	2/7/08			36,375			8.97			2/7/15
	3/31/11			6,689			8.97			3/31/18
	12/20/12			35,677			8.97			12/20/22
	Equity Incentive Plans
	On September 12, 1997, the Company's Board of Directors adopted the Stock Option Plan (the "1997 Plan") to create an additional incentive for key employees, directors and consultants or advisors of the Company. Both incentive stock options, which meet the requirements of Section 422 of the Internal Revenue Code, and nonqualified stock options, could be granted under the 1997 Plan. The exercise price of all options was determined by the Board of Directors, provided that such price for incentive stock options was not to be less than the estimated fair market value of the Company’s stock on the date of grant. The options vest based on terms in the stock option agreements (generally over four years) and are exercisable after they have been granted for up to ten years from the date of grant. The 1997 Plan expired on September 12, 2007.
	On October 25, 2007, the Company's Board of Directors adopted the 2007 Stock Incentive Plan (the "2007 Plan") to replace the expired 1997 Plan. The terms of the 2007 Plan are consistent with those of the 1997 Plan. On May 24, 2012, the Company's Board of Directors adopted, and stockholders subsequently approved, the 2012 Equity Incentive Plan (the "2012 Plan"). The 2012 Plan became effective immediately upon the completion of the IPO in January 2013, and no further shares may be issued under the 2007 Plan. The 2012 Plan will terminate on May 24, 2022, unless sooner terminated by the Company's Board of Directors.
	Restricted Stock Units
	During the nine months ended September 30, 2013, the Company's Board of Directors granted 142,869 restricted stock units ("RSUs") to certain of the Company's employees and directors at a weighted average grant-date fair value of $7.07 per share. During the nine months ended September 30, 2013, the Company issued approximately 8,500 shares of outstanding common stock upon the vesting and settlement of RSUs, with a total fair value of $47,000.
	Each RSU represents the contingent right to receive one share of common stock of the Company. The RSUs granted to the Company's employees generally vest 100% on the three-year anniversary of the grant date. The RSUs granted to non-employee directors generally vest quarterly over a one-year period from the date of grant. The fair value of RSUs is estimated based on the closing price of the underlying common stock on the date of grant. For the purposes of expense recognition, the total number of shares expected to vest is adjusted for estimated forfeitures and the expense is recognized on a straight-line basis over the requisite service period. As of September 30, 2013, there was $0.6 million of unrecognized compensation expense, net of estimated forfeitures, related to unvested RSUs, which is expected to be recognized over a weighted-average period of 2.7 years.
	Stock Options
	During the nine months ended September 30, 2013, the Company's Board of Directors granted stock options under the 2012 Plan to purchase an aggregate of 511,443 shares to employees and directors at a weighted average exercise price of $8.01 per share and a weighted average grant-date fair value of $3.52 per share. During the nine months ended September 30, 2013, the Company issued approximately 253,000 shares of outstanding common stock upon the exercise of stock options, at a weighted average exercise price of $2.58 a share.
	The Company estimates the fair value of its stock options on the grant date using the Black-Scholes option pricing model. The fair value of both employee and non-employee director options is then amortized on a straight-line basis over the requisite service period of the awards. The exercise prices of all stock options granted was equal to the closing market price of the underlying common stock on the grant date. The weighted average assumptions used in the Black-Scholes valuation model for equity awards granted for the nine months ended September 30, 2013 and 2012 are shown in the table below. As of September 30, 2013, there was $1.6 million of unrecognized compensation expense, net of estimated forfeitures, related to non-vested stock options, which is expected to be recognized over a weighted-average period of 2.4 years.
	The Company determined the options' life based upon the use of the simplified method. As a newly public company, sufficient history to estimate the volatility and dividend yield of the Company's common stock is not available. The Company elected to utilize a peer group of comparable companies as a basis for the expected volatility assumption and dividend yield. The Company intends to continue to consistently apply this process using the peer group of comparable companies until a sufficient amount of historical information becomes available. The risk-free interest rate is based upon the yield of an applicable U.S. Treasury instrument.
	The fair value of these stock options was estimated using the following weighted average assumptions:
		Nine Months Ended September 30,
		2013			2012
	Expected dividend yield	0	%		0	%
	Risk-free interest rate	1.2	%		0.8	%
	Expected volatility	45.5	%		51.2	%
	Expected life (in years)	5.8			5.6
	The Company recognized non-cash stock-based compensation expense, for both RSUs and stock options, to employees in its research and development, sales and marketing and general and administrative functions as follows (in thousands):
		Three Months Ended September 30,							Nine Months Ended September 30,
		2013				2012			2013			2012
	Cost of revenues	$	10			$	8		$	28		$	35
	Research and development	132				89			372			359
	Sales and marketing	73				44			163			198
	General and administrative	298				123			502			289
	Total:	$	513			$	264		$	1,065		$	881
	The following table summarizes information about stock options outstanding as of September 30, 2013:
		Total Options Outstanding						Options Exercisable
	Range of	Number		Weighted		Weighted		Number	Weighted		Weighted
	Exercise Prices	of		Average		Average		of	Average		Average
		Options		Exercise		Remaining		Options	Exercise		Remaining
				Price		Life in Years			Price		Life in Years
	$1.87 – $2.45	281,522		$2.36				281,522	$2.36
	$2.49	299,904		2.49				299,904	2.49
	$3.88 – $4.23	261,564		3.92				261,564	3.92
	$5.07 – $5.55	183,675		5.24				79,334	5.14
	$5.63 – $5.98	227,947		5.66				193,045	5.63
	$6.68 - $6.89	218,583		6.83				152,418	6.85
	$9.01	74,134		9.01				55,800	9.01
	$9.65 – $9.84	236,334		9.68				60,426	9.74
	$11.11 – $11.44	222,793		11.4				165,849	11.4
	$12.80	79,829		12.8				42,525	12.8
		2,086,285		6.09		5.6		1,592,387	5.34		4.5

RelatedParty_Transactions

Related-Party Transactions	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related-Party Transactions	'
	Related-Party Transactions
	On May 12, 1997, the Company entered into a license agreement with North Carolina State University ("North Carolina State"). Under the terms of the agreement, North Carolina State granted the Company an exclusive, worldwide license, including patent rights, to technology related to measuring lipoprotein levels using NMR spectroscopy. The Company paid an initial license fee and made a commitment to fund future collaborative research for $25,000. The Company is required to pay certain royalties based on net sales, subject to a minimum annual royalty. The agreement also requires the Company to commercialize the patent rights. The agreement shall remain in effect until the expiration of the last-to-expire patent covered by the agreement. Dr. James Otvos, the Chief Scientific Officer, and a principal stockholder, of the Company, is an Adjunct Professor of Biochemistry at North Carolina State. There was $2,500 in accrued license royalties due to North Carolina State as of September 30, 2013. As of December 31, 2012, the accrued license royalties due to North Carolina State totaled $5,000.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	The Company computes its provision for income taxes by applying the estimated annual effective tax rate, adjusted for any material items. For each of the nine months ended September 30, 2013 and 2012, no provision or benefits for income taxes have been recorded. The Company has recorded a full valuation allowance against its net deferred tax assets based on the Company's assessment regarding the realizability of these net deferred tax assets in future periods. The Company also does not anticipate being subject to the alternative minimum tax due to the available exemptions such as research and development credit carryforwards. At September 30, 2013, the Company had no unrecognized tax benefits that would affect the Company's effective tax rate. The Company's effective tax rate for each of the nine months ended September 30, 2013 and 2012 was 0%.

Employee_Benefit_Plan

Employee Benefit Plan	9 Months Ended
	Sep. 30, 2013
Postemployment Benefits [Abstract]	'
Employee Benefit Plan	'
	Employee Benefit Plan
	The Company has adopted a defined contribution plan (the "Employee Benefit Plan") that qualifies under Section 401(k) of the Internal Revenue Code. All employees of the Company who have attained 21 years of age are eligible for participation in the Employee Benefit Plan after thirty days of employment.
	Under the Employee Benefit Plan, participating employees may defer up to the Internal Revenue Service annual contribution limit. On July 1, 2012, the Company increased its employer match from 25% to 50% of the first 6% that an eligible participant contributes each year. The Company paid $0.2 million during each of the three months ended September 30, 2013 and 2012, and $0.5 million and $0.3 million during the nine months ended September 30, 2013 and 2012, respectively, in employer match contributions to the Employee Benefit Plan.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	Leases
	The Company leases an aggregate of approximately 83,000 square feet of office and laboratory space under a lease agreement that expires on September 30, 2022. In connection with the lease, the Company obtained a $1.5 million letter of credit secured by restricted cash (see Note 6). In June 2013, the required amount for the letter of credit secured by restricted cash was reduced to $0.5 million.
	The Company also leases office equipment and software licenses through operating leases.
	Rent expense is calculated on a straight-line basis over the term of the lease. The Company incurred rent expense of $0.3 million during each of the three months ended September 30, 2013 and 2012, and $0.8 million and $0.9 million for the nine months ended September 30, 2013 and 2012, respectively.
	Property and equipment includes the following amounts financed under capital leases as of (in thousands):
		September 30, 2013			December 31, 2012
	Office equipment	$	182		$	182
	Less accumulated depreciation	(182		)	(182		)
	Property and equipment under capital leases, net	$	—		$	—
	Purchase Obligations
	The Company has outstanding purchase obligations relating to the purchase of hardware components from third-party manufacturers for the Vantera system in the amount of $4.4 million as of September 30, 2013.
	Legal Contingencies
	The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company's management does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations or cash flows.
	Indemnification
	In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but that have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. The Company may, however, record charges in the future as a result of these indemnification obligations.
	In accordance with its Certificate of Incorporation and Bylaws, the Company has indemnification obligations to its directors, and has the authority to indemnify its officers and employees, for certain events or occurrences, subject to certain limits, while they are serving at the Company's request in such capacity. There have been no claims to date, and the Company has director and officer insurance that enables it to recover a portion of any amounts paid for future potential claims.
	In addition to the indemnification provided for in its Certificate of Incorporation and Bylaws, the Company has also entered into separate indemnification agreements with each of its directors, which agreements provide such directors with indemnification rights under certain circumstances.

Description_of_Business_and_Si1

Description of Business and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation	'
	The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include all adjustments necessary for the fair presentation of the Company's financial position, results of operations and cash flows for the periods presented.
Use of Estimates	'
	In preparing the financial statements, management must make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates and assumptions used.
Customers and Payors	'
	The Company provides diagnostic tests to a broad range of customers. A majority of these tests are comprised of orders generated through clinical diagnostic laboratory customers and clinicians. The Company also receives requests from academic institutions as well as pharmaceutical companies. In most cases, the customer that orders the tests is not responsible for the payments for services. The Company considers a party that refers a test to it to be a “customer” and a party that reimburses the Company as a “payor.” Depending on the billing arrangement and applicable law, the payor may be (i) a clinical diagnostic laboratory, (ii) a third party responsible for providing health insurance coverage to patients, such as a health insurance plan or the traditional Medicare or Medicaid program, (iii) the physician or (iv) the patient or other party (such as academic institutions or pharmaceutical companies) who requested the test from the Company.
Revenue Recognition	'
	The Company currently derives revenue from sales of its NMR LipoProfile test to clinical diagnostic laboratories and clinicians for use in patient care, from sales of ancillary tests for use in patient care requested in conjunction with the NMR LipoProfile test and from contract research arrangements.
	Revenues from diagnostic tests for patient care, which consist of sales of the NMR LipoProfile test performed at the Company's laboratory facility and at third party clinical diagnostic laboratory facilities (see “The Vantera System Placement Arrangements” below) and sales of ancillary tests, are recognized on the accrual basis when the following revenue recognition criteria are met: (1) persuasive evidence that an arrangement exists; (2) services have been rendered or at the time final results are reported; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Testing services provided for patient care are covered by clinical diagnostic laboratories through negotiated contracts with commercial insurance carriers, programs with commercial insurance carriers (including managed care organizations) and various governmental programs, primarily Medicare.
	Billings for diagnostic tests for patient care under governmental and physician-based programs are included in revenues net of contractual adjustments. These contractual adjustments represent the difference between the final settlement amount paid by the program and the estimated settlement amount based on either the list price for tests performed or the reimbursement rate set by commercial insurance carriers or governmental programs. Estimated contractual adjustments are updated either upon notification from payors as to changes in existing reimbursement rates, which are typically received prior to changes going into effect, or upon a material variance between the final settlement and the estimated contractual adjustment originally established when the revenues were recognized. To date, the Company's final settlement adjustments have not been material.
	Revenues from contract research arrangements are generally derived from studies conducted by academic institutions and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given agreement. The Company's output, measured in terms of full-time equivalent level of effort or processing a set of diagnostic tests under a contractual protocol, typically triggers payment obligations under these agreements. Revenues are recognized as costs are incurred or diagnostic tests are processed. Contract research costs include all direct material and labor costs, equipment costs and fringe benefits. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met.
	Billing for diagnostic testing services for patient care is complex. In most cases, tests are performed in advance of payment and without certainty as to the outcome of the billing process, which may negatively affect revenues, cash flow and profitability. Payments are received from a variety of payors, including clinical diagnostic laboratories, commercial insurance carriers (including managed care organizations), governmental payors (primarily Medicare) and individual patients. Each payor typically has different billing requirements, and the billing requirements of many payors have become increasingly stringent.
	The Company generally assumes the financial risk related to collection, including the potential uncollectibility of accounts and the other complex factors identified above. For sales of its NMR LipoProfile test to clinical diagnostic laboratories, the clinical diagnostic laboratories are responsible for obtaining reimbursement from third-party payors or directly from patients. Delays in collection and uncollectible bills may negatively affect the Company's revenues, cash flow and profitability.
	The Vantera System Placement Arrangements
	The Company's automated clinical analyzer, the Vantera system, was cleared by the FDA in August 2012 and became commercially available in December 2012. The Company started placing the Vantera system on-site with certain qualified national and regional clinical diagnostic laboratories as well as leading medical centers and hospital outreach laboratories during the second quarter of 2013.
	The Company's Vantera system placement arrangements (or “placement arrangements”) are generally negotiated and accounted for as operating leases. Arrangement consideration is determined based on the test volume and the negotiated price-per-reportable NMR LipoProfile test result. The placement arrangements typically include lease and non-lease deliverables. Lease deliverables include the right to use the Vantera system and related maintenance and support, while non-lease deliverables consist of the NMR LipoProfile test and consumables. Lease deliverables are accounted for in accordance with specific leasing guidance while non-lease deliverables are accounted for in accordance with the multiple-element arrangement guidance.
	The Company evaluates each non-lease deliverable to determine whether it represents a separate unit of accounting. A deliverable is considered a separate unit of accounting when the delivered item has stand-alone value and delivery of the undelivered element is probable and within the Company's control. The Company has determined that both the NMR LipoProfile test and consumables have separate units of accounting. The NMR LipoProfile test is the Company's most significant deliverable under these placement arrangements.
	The Company allocates revenue to each deliverable at the inception of the placement arrangement, based on its estimated stand-alone value in relation to the combined estimated stand-alone value of all deliverables, or the relative selling price method. Revenue allocated to each deliverable is then recognized when the basic revenue recognition criteria, as described above, is met for each deliverable.
	The Company applies the following selling price hierarchy in determining the selling price for each deliverable:
	•	Vendor-specific objective evidence (“VSOE”) if available-the price charged for a deliverable when it is sold separately and, in other instances, using the price established by management having the relevant authority.
	•	Third-party evidence (“TPE”) if VSOE is not available-the price of the vendor's or any competitor's largely interchangeable products or services in standalone sales to similarly situated customers.
	•	Estimated selling price (“ESP”) if neither VSOE or TPE is available-the price best estimated by the vendor and at which the vendor would transact if the deliverable would have been sold by the vendor regularly on a standalone basis.
	The Company has determined that only the selling price of its NMR LipoProfile test is based on VSOE. The Company does not sell the license to use the Vantera system, the consumables or related maintenance and support separately on a regular basis and therefore it does not have the evidence to support VSOE for these deliverables. Due to the high degree of customization involved with these deliverables, the Company has determined that there is no comparable TPE for these deliverables. Since these deliverables have neither VSOE nor TPE, the allocation of revenue to them has been based on the Company's ESP.
	The Company's process for determining ESP for its deliverables considers all reasonably available information including both market data and conditions, as well as entity specific factors that may vary depending upon the facts and circumstances related to each deliverable. Key factors considered in developing ESP relating to deliverables include cost structures, established pricing and approval policies and customization of the product or service and industry pricing. The Company regularly reviews ESP and maintains internal controls over the establishment and updates of these estimates.
Shipping and Handling	'
	The Company does not bill its customers for shipping and handling charges. All charges relating to inbound and outbound freight costs are incurred by the Company and recorded within cost of revenues.
Fair Value of Financial Instruments	'
	The Company measures certain financial assets and liabilities at fair value based on the price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.
Cash and Cash Equivalents	'
	The Company invests its available cash balances in cash, certificates of deposits and money market funds. The Company considers all highly liquid instruments purchased with original maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents are stated at cost and the carrying amounts approximate fair value. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.
Accounts Receivable	'
	Accounts receivable are primarily amounts due from clinical diagnostic laboratories, commercial insurance companies (including managed care organizations), governmental programs (primarily Medicare), physicians, and individual patients.
	Accounts receivable are reported net of an allowance for uncollectible accounts and contractual allowance adjustments. The process of estimating the collection of accounts receivable involves significant assumptions and judgments. Specifically, the accounts receivable allowance is based on management's analysis of current and past due accounts, collection experience in relation to amounts billed, changes in reimbursement levels, known contract terms, channel mix, any specific customer collection issues that have been identified and other relevant information. The Company's provision for uncollectible accounts is recorded as bad debt expense and included in general and administrative expenses. Historically, the Company has not experienced significant credit loss related to its customers or payors. Although the Company believes amounts provided are adequate, the ultimate amounts of uncollectible accounts receivable could be in excess of the amounts provided.
Inventories	'
	Inventories consist of materials and spare parts to service the Vantera system. Inventories are valued at the lower of cost or net realizable value. The cost of inventories is maintained using the average-cost method.
Property and Equipment	'
	Property and equipment are stated at cost. Property and equipment financed under capital leases are initially recorded at the present value of minimum lease payments at the inception of the lease. Amortization of assets financed under capital leases is included with purchased property and equipment as part of depreciation and amortization.
	Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Property and equipment under capital leases and leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life of the asset. Depreciable lives range from three to seven years for laboratory equipment, customer-use assets, office equipment and furniture and fixtures and three years for software.
Intangible Assets	'
	Intangible assets include patent costs, trademark costs and technology licenses that are capitalized and amortized over estimated useful lives (generally nine to twenty years) using the straight-line method. Patent costs are expensed if the patent is not granted. On an ongoing basis, the Company assesses the recoverability of its intangible assets by determining its ability to generate undiscounted future cash flows sufficient to recover the unamortized balances over the remaining useful lives. Intangible assets determined to be unrecoverable are expensed in the period in which the determination is made.
Impairment of Long-Lived Assets	'
	The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may be impaired and assesses their recoverability based upon anticipated future cash flows. If changes in circumstances lead the Company to believe that any of its long-lived assets may be impaired, the Company will (a) evaluate the extent to which the remaining book value of the asset is recoverable by comparing the future undiscounted cash flows estimated to be associated with the asset to the asset's carrying amount and (b) write-down the carrying amount to market value or discounted cash flow value to the extent necessary.
Deferred Offering Costs	'
	Deferred offering costs represent legal, accounting and other direct costs related to the Company's efforts to raise capital through the IPO. Costs related to the Company's IPO activities were deferred until the completion of the IPO, at which time they were reclassified to additional paid-in capital as a reduction of the IPO proceeds.
Redeemable Convertible Preferred Stock	'
	The Company had historically classified its redeemable convertible preferred stock, for which the Company did not control the redemption, outside of permanent equity. The Company had recorded redeemable convertible preferred stock at fair value upon issuance, net of any issuance costs or discounts, and the carrying value was increased by periodic accretion to its redemption value. These increases were effected through charges against additional paid-in capital. Upon closing of the IPO, all outstanding redeemable convertible preferred stock as well as convertible preferred stock was reclassified to additional paid-in capital.
Preferred Stock Warrant Liability	'
	The Company had historically accounted for its freestanding warrants to purchase the Company's Series E and Series F Redeemable Convertible Preferred Stock as liabilities at fair value on the accompanying balance sheets. The warrants were subject to re-measurement at each balance sheet date, and the change in fair value, if any, was recognized as other income or expense. As a result of the IPO, all preferred stock warrant liability was reclassified to additional paid-in capital upon the conversion of warrants to purchase preferred stock into warrants to purchase common stock.
Research and Development Expenses	'
	Research and development expenses include all costs associated with the development of NMR technology products and are charged to expense as incurred. Research and development expenses include direct costs and an allocation of indirect costs, including amortization, depreciation, telephone, rent, supplies, insurance and repairs and maintenance.
Financing Costs	'
	The Company capitalizes direct financing costs, which are included as other noncurrent assets on the Company's balance sheets. The Company accretes debt discounts, which are included as a direct deduction from the face amount of the financing. Debt financing costs and debt discounts are deferred and amortized to interest expense using the effective interest method over the life of the related debt. The related expense is included in interest expense in the Company's statements of comprehensive (loss) income.
Income Taxes	'
	The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company's assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.
	The Company has adopted the accounting guidance for uncertainties in income taxes, which proscribes a recognition threshold and measurement process for recording uncertain tax positions taken, or expected to be taken, in a tax return in the financial statements. Additionally, the guidance also proscribes a new treatment for the derecognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. The Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained.
Advertising	'
	Advertising costs, which are included in sales and marketing expenses, are expensed as incurred.
Stock-Based Compensation	'
	The Company accounts for stock-based compensation arrangements with employees and non-employee directors using a fair value method that requires the recognition of compensation expense for costs related to all stock-based payments, including stock options and restricted stock units. The fair value method requires the Company to estimate the fair value of stock options on the date of grant using an option pricing model. The fair value of restricted stock units is estimated based on the closing price of the Company's stock on the date of grant, and for the purposes of expense recognition, the total new number of shares expected to vest is adjusted for estimated forfeitures.
	Stock-based compensation costs for stock options are based on the fair value of the underlying option calculated using the Black-Scholes option-pricing model on the date of grant for stock options and recognized as expense on a straight-line basis over the requisite service period, which is the vesting period. Determining the appropriate fair value model and related assumptions requires judgment, including estimating stock price volatility, forfeiture rates and expected term. The expected volatility rates are estimated based on the actual volatility of comparable public companies over the expected term. The expected term represents the average time that options are expected to be outstanding based on the mid-point between the vesting date and the end of the contractual term of the award. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has not paid dividends and does not anticipate paying a cash dividend in the foreseeable future and, accordingly, uses an expected dividend yield of zero. The risk-free interest rate is based on the rate of U.S. Treasury securities with maturities consistent with the estimated expected term of the awards. The measurement of nonemployee share-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense over the period over which services are received.
Segment Reporting	'
	The Company operates in one operating segment. The Company's chief operating decision maker (the “CODM”), currently its interim chief executive officer, manages the Company's operations on an integrated basis for purposes of allocating resources. When evaluating the Company's financial performance, the CODM reviews separate revenue information for the Company's patient care testing and its research services, while all other financial information is reviewed on a combined basis. All of the Company's principal operations and decision-making functions are located in the United States. Accordingly, the Company has determined that it has a single reporting segment.
Recent Accounting Pronouncements	'
	In October 2012, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2012-04, Technical Corrections and Improvements. The amendments in this update cover a wide range of topics in the Accounting Standards Codification. These amendments include technical corrections and improvements to the Accounting Standards Codification and conforming amendments related to fair value measurements. For public companies, the amendments that are subject to the transition guidance were effective for reporting periods beginning after December 15, 2012. Accordingly, the Company adopted this update on January 1, 2013. Adoption of this new guidance had no material impact on the Company's financial statements.
	In February 2013, the FASB issued ASU No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. The amendments in this update are intended to improve the reporting of reclassifications out of accumulated other comprehensive income by requiring an entity to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required to be reclassified in its entirety to net income. For other amounts that are not required to be reclassified in their entirety to net income in the same reporting period, an entity is required to cross-reference other disclosures required that provide additional detail about those amounts. This would be the case when a portion of the amount reclassified out of accumulated other comprehensive income is reclassified to a balance sheet account instead of directly to income or expense in the same reporting period.   For public companies, the amendments that are subject to this update were effective for interim and annual reporting periods beginning after December 15, 2012. Accordingly, the Company adopted this update on January 1, 2013. Adoption of this new guidance had no material impact on the Company's financial statements.
	In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. The amendments in this update provide clarification, and are intended to reduce diversity in practice, on the financial statement presentation of unrecognized tax benefits. The guidance specifies that an unrecognized tax benefit (or a portion thereof) shall be presented in the financial statements as a reduction to a deferred tax asset when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. If such deferred tax asset is not available at the reporting date to settle additional income taxes resulting from the disallowance of a tax position, or the entity does not plan to use the deferred tax asset for such purpose given the option, the unrecognized tax benefit shall be presented in the financial statements as a liability and shall not be combined with deferred tax assets. The assessment of whether a deferred tax asset is available is based on the unrecognized tax benefit and deferred tax asset that exist at the reporting date and should be made presuming disallowance of the tax position at the reporting date. For public companies, the amendments that are subject to this update are effective for interim and annual reporting periods beginning after December 15, 2013, with early adoption permitted. The Company’s current practice is consistent with the amendments in this update. The Company expects that the new guidance will have no material impact on the Company’s financial statements.

Description_of_Business_and_Si2

Description of Business and Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2013
Revenues [Member]	'
Concentration Risk [Line Items]	'
Schedules of Concentration of Risk, by Risk Factor	'
	Revenues from customers representing 10% or more of total revenues for the respective periods, are summarized as follows:
		Three Months Ended September 30,				Nine Months Ended September 30,
		2013		2012		2013		2012
	Health Diagnostics Laboratory	33	%	34	%	34	%	32	%
	LabCorp	30		29		30		29
Accounts Receivable [Member]	'
Concentration Risk [Line Items]	'
Schedules of Concentration of Risk, by Risk Factor	'
	The Company’s accounts receivable due from these significant customers as a percentage of total accounts receivable was as follows as of the dates indicated:
		September 30, 2013		December 31, 2012
	Health Diagnostics Laboratory	37	%	*
	LabCorp	19		39	%
	* Less than 10%.

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements, Recurring and Nonrecurring	'
	The following table sets forth the Company's financial instruments that were measured at fair value as of September 30, 2013 and December 31, 2012 by level within the fair value hierarchy (in thousands):
		September 30, 2013							December 31, 2012
		Level I			Level III		Total		Level I		Level III		Total
	Assets
	Certificates of deposits	$	—		$	—	$	—	$	5,253	$	—	$	5,253
	Money market funds	502			—		502		21,016		—		21,016
	Total assets measured at fair value	$	502		$	—	$	502	$	26,269	$	—	$	26,269
	Liabilities
	Preferred stock warrant liability	$	—		$	—	$	—	$	—	$	412	$	412
	Total liabilities measured	$	—		$	—	$	—	$	—	$	412	$	412
	at fair value
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	'
	The change in the fair value of the Level III preferred stock warrant liability is summarized below (in thousands):
		Nine Months Ended September 30,
		2013			2012
	Fair value at beginning of period	$	412		$	229
	Reclassification to additional paid in capital upon the IPO	(410		)	—
	Change in fair value recorded in other expense	(2		)	233
	Fair value at end of period	$	—		$	462

Cash_and_Cash_Equivalents_Tabl

Cash and Cash Equivalents (Tables)	9 Months Ended
	Sep. 30, 2013
Cash and Cash Equivalents [Abstract]	'
Schedule of Cash and Cash Equivalents	'
	Cash and cash equivalents consist of the following as of (in thousands):
		September 30, 2013		December 31, 2012
	Cash	$	51,574	$	4
	Certificates of deposit	—		5,253
	Money market funds	—		19,511
	Total cash and cash equivalents	$	51,574	$	24,768

Accounts_Receivable_and_Revenu1

Accounts Receivable and Revenues (Tables)	9 Months Ended
	Sep. 30, 2013
Receivables [Abstract]	'
Schedule of Accounts Receivable, Net	'
	Accounts receivable, net, consists of the following as of (in thousands):
		September 30, 2013			December 31, 2012
	Accounts receivable	$	7,617		$	6,526
	Less allowance for uncollectible accounts receivable	(1,106		)	(1,377		)
	Accounts receivable, net	$	6,511		$	5,149
Allowance for Uncollectible Accounts Receivable Rollforward	'
	Activity for the allowance for uncollectible accounts receivable is as follows (in thousands):
		Nine Months Ended September 30, 2013			Year Ended December 31, 2012
	Balance at beginning of period	$	1,377		$	1,676
	Provision for bad debt expense	212			818
	Write-off, net of recoveries	(483		)	(1,117		)
	Balance at end of period	$	1,106		$	1,377
Schedule of Gross and Net Revenue	'
	Revenues consist of the following (in thousands):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013			2012
	Gross billings	$	13,112		$	13,985		$	40,711		$	42,692
	Less contractual adjustments	(374		)	(421		)	(1,046		)	(1,451		)
	Revenues	$	12,738		$	13,564		$	39,665		$	41,241

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Schedule of Property and Equipment	'
	Property and equipment consists of the following as of (in thousands):
		September 30, 2013			December 31, 2012
	Laboratory equipment	$	9,605		$	9,415
	Office equipment, furniture and fixtures	3,416			3,497
	Leasehold improvements	3,229			2,652
	Software	2,154			1,793
	Customer-use assets	328			—
	Construction in progress	6,167			5,778
		24,899			23,135
	Less accumulated depreciation	(12,319		)	(11,642		)
	Property and equipment, net	$	12,580		$	11,493

Accrued_Expenses_Tables

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Schedule of Accrued Expenses	'
	Accrued expenses consist of the following as of (in thousands):
		September 30, 2013		December 31, 2012
	Accrued wages and benefits	$	2,072	$	1,541
	Accrued bonus	528		2,200
	Other accrued liabilities	1,220		1,608
	Total accrued expenses	$	3,820	$	5,349

LongTerm_Debt_and_Line_of_Cred1

Long-Term Debt and Line of Credit (Tables)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Schedule of Long-term Debt	'
	Long-term debt consists of the following (in thousands):
		September 30, 2013			December 31, 2012
	Long-term debt to financial institutions	$	16,000		$	16,000
	Less unamortized debt discount	(212		)	(292		)
	Less current maturities of long-term debt	(3,904		)	—
	Long-term debt, less current maturities and unamortized debt discount	$	11,884		$	15,708

Net_Loss_Income_Per_Share_Tabl

Net (Loss) Income Per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Schedule of Antidilutive Common Share Equivalents	'
	Because of their anti-dilutive effect, the following common stock equivalents, consisting of convertible preferred shares, redeemable convertible preferred shares, common stock options, warrants and restricted stock units, have been excluded from the diluted loss per share calculations for the respective periods presented:
		Three Months Ended September 30,						Nine Months Ended September 30,
	Anti-Dilutive Common Share Equivalents:	2013			2012			2013		2012
	Convertible Preferred Stock (Series A, A-1, B, B-1, C, and C-1)	—			1,222,211			—		1,222,211
	Redeemable Convertible Preferred Stock (Series D, D-1, E and F)	—			5,763,606			—		5,763,606
	Common Stock Options and Warrants	2,171,715			2,445,633			2,171,715		327,579
	Restricted Stock Units	112,592			—			112,592		—
		2,284,307			9,431,450			2,284,307		7,313,396
Schedule of Net (Loss) Income Per Share	'
	A reconciliation of the numerator and denominator used in the computation of basic and diluted net (loss) income per share allocable to common stockholders follows (in thousands, except share and per share data):
		Three Months Ended September 30,							Nine Months Ended September 30,
		2013				2012			2013			2012
	Historical net (loss) income per share:
	Numerator:
	Net (loss) income	$	(4,627	)		$	(481	)	$	(9,919	)	$	1,057
	Less: Undistributed earnings allocated to participating preferred shares	—				—			—			(850		)
	Net (loss) income attributable to common stockholders – basic	(4,627		)		(481		)	(9,919		)	207
	Add: Undistributed earnings re-allocated to common stockholders	—				—			—			122
	Net (loss) income attributable to common stockholders – diluted	$	(4,627	)		$	(481	)	$	(9,919	)	$	329
	Denominator:
	Weighted average common shares outstanding – basic	14,727,286				1,704,689			14,727,286			1,704,689
	Dilutive effect of common stock equivalent shares resulting from common stock options and warrants	—				—			—			1,446,413
	Weighted average common shares outstanding – diluted	14,727,286				1,704,689			14,727,286			3,151,102
	Net (loss) income per common share:
	Net (loss) income per share attributable to common stockholders – basic	$	(0.31	)		$	(0.28	)	$	(0.67	)	$	0.12
	Net (loss) income per share attributable to common stockholders – diluted	$	(0.31	)		$	(0.28	)	$	(0.67	)	$	0.1

Equity_Transactions_and_ShareB1

Equity Transactions and Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Fair Value Assumptions and Methodology	'
	The fair values of outstanding Series E and Series F Redeemable Convertible Preferred Stock warrants were estimated using the Black-Scholes option-pricing model with the following assumptions as of:
			December 31, 2012
	Expected term (in years)		0.25-0.5
	Risk-free interest rate		0.0%-0.1%
	Expected volatility		30	%
	Expected dividend rate		0	%
Schedule of Stockholders' Equity Note, Warrants or Rights	'
	As of September 30, 2013, the following warrants to purchase common stock were outstanding:
	Issuance Date			Number of Shares			Exercise Price			Expiration Date
	12/13/06			6,689			$	8.97		12/13/13
	2/7/08			36,375			8.97			2/7/15
	3/31/11			6,689			8.97			3/31/18
	12/20/12			35,677			8.97			12/20/22
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	'
	The fair value of these stock options was estimated using the following weighted average assumptions:
		Nine Months Ended September 30,
		2013			2012
	Expected dividend yield	0	%		0	%
	Risk-free interest rate	1.2	%		0.8	%
	Expected volatility	45.5	%		51.2	%
	Expected life (in years)	5.8			5.6
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	'
	The Company recognized non-cash stock-based compensation expense, for both RSUs and stock options, to employees in its research and development, sales and marketing and general and administrative functions as follows (in thousands):
		Three Months Ended September 30,							Nine Months Ended September 30,
		2013				2012			2013			2012
	Cost of revenues	$	10			$	8		$	28		$	35
	Research and development	132				89			372			359
	Sales and marketing	73				44			163			198
	General and administrative	298				123			502			289
	Total:	$	513			$	264		$	1,065		$	881
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range	'
	The following table summarizes information about stock options outstanding as of September 30, 2013:
		Total Options Outstanding						Options Exercisable
	Range of	Number		Weighted		Weighted		Number	Weighted		Weighted
	Exercise Prices	of		Average		Average		of	Average		Average
		Options		Exercise		Remaining		Options	Exercise		Remaining
				Price		Life in Years			Price		Life in Years
	$1.87 – $2.45	281,522		$2.36				281,522	$2.36
	$2.49	299,904		2.49				299,904	2.49
	$3.88 – $4.23	261,564		3.92				261,564	3.92
	$5.07 – $5.55	183,675		5.24				79,334	5.14
	$5.63 – $5.98	227,947		5.66				193,045	5.63
	$6.68 - $6.89	218,583		6.83				152,418	6.85
	$9.01	74,134		9.01				55,800	9.01
	$9.65 – $9.84	236,334		9.68				60,426	9.74
	$11.11 – $11.44	222,793		11.4				165,849	11.4
	$12.80	79,829		12.8				42,525	12.8
		2,086,285		6.09		5.6		1,592,387	5.34		4.5

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Capital Leased Assets	'
	Property and equipment includes the following amounts financed under capital leases as of (in thousands):
		September 30, 2013			December 31, 2012
	Office equipment	$	182		$	182
	Less accumulated depreciation	(182		)	(182		)
	Property and equipment under capital leases, net	$	—		$	—

Description_of_Business_and_Si3

Description of Business and Significant Accounting Policies (Details) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Jan. 30, 2013

Jan. 10, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Jan. 30, 2013

Sep. 30, 2013

Jan. 30, 2013

Jan. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

segments

Stock Options [Member]

Stock Options [Member]

Minimum [Member]

Maximum [Member]

Laboratory Equipment [Member]

Laboratory Equipment [Member]

Customer-Use Assets [Member]

Customer-Use Assets [Member]

Office Equipment, Furniture and Fixtures [Member]

Office Equipment, Furniture and Fixtures [Member]

Software [Member]

Convertible Preferred Stock [Member]

Series F Redeemable Convertible Preferred Stock [Member]

IPO [Member]

IPO Overallotment [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

LabCorp [Member]

LabCorp [Member]

LabCorp [Member]

LabCorp [Member]

LabCorp [Member]

LabCorp [Member]

Health Diagnostics Laboratory [Member]

Health Diagnostics Laboratory [Member]

Health Diagnostics Laboratory [Member]

Health Diagnostics Laboratory [Member]

Health Diagnostics Laboratory [Member]

Health Diagnostics Laboratory [Member]

Revenues [Member]

Revenues [Member]

Revenues [Member]

Revenues [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Revenues [Member]

Revenues [Member]

Revenues [Member]

Revenues [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Organization, Consolidation and Presentation of Financial Statements [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reverse stock split ratio

'

0.485

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shipping and handling costs

'

'

$200,000

$400,000

$1,000,000

$1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred offering costs

'

'

0

'

0

'

3,151,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of operating segments

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Advertising expense

'

'

200,000

400,000

700,000

700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial Public Offering

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock sold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,750,000

750,000

'

'

'

'

'

'

'

'

'

'

'

'

Price per share (in usd per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$9

'

'

'

'

'

'

'

'

'

'

'

'

'

Value of new issues

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

51,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate gross proceeds from public offering

44,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Underwriting discounts and commissions

3,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Offering expenses

4,000,000

'

'

'

4,443,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares converted to common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,892,682

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issued from conversion of convertible securities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,994,559

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payment of accrued dividends

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property and Equipment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property and equipment, useful life

'

'

'

'

'

'

'

'

'

'

'

'3 years

'7 years

'3 years

'7 years

'3 years

'7 years

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible Assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible asset, useful life

'

'

'

'

'

'

'

'

'

'9 years

'20 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of intangible assets

'

'

$6,000

$4,000

$17,000

$14,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-Based Compensation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected dividend yield

'

'

'

'

'

'

'

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Concentration of Credit Risks and Other Risks

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Concentration risk, percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30.00%

29.00%

30.00%

29.00%

19.00%

39.00%

33.00%

34.00%

34.00%

32.00%

37.00%

'

[1]

[1]

* Less than 10%.

Fair_Value_Measurement_Financi

Fair Value Measurement (Financial Instruments Measured at Fair Value) (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Level I [Member]	'	'
Assets	'	'
Total assets measured at fair value	$502	$26,269
Liabilities	'	'
Preferred stock warrant liability	0	0
Total liabilities measured at fair value	0	0
Level III [Member]	'	'
Assets	'	'
Total assets measured at fair value	0	0
Liabilities	'	'
Preferred stock warrant liability	0	412
Total liabilities measured at fair value	0	412
Total [Member]	'	'
Assets	'	'
Total assets measured at fair value	502	26,269
Liabilities	'	'
Preferred stock warrant liability	0	412
Total liabilities measured at fair value	0	412
Certificates of Deposits [Member] | Level I [Member]	'	'
Assets	'	'
Cash and cash equivalents	0	5,253
Certificates of Deposits [Member] | Level III [Member]	'	'
Assets	'	'
Cash and cash equivalents	0	0
Certificates of Deposits [Member] | Total [Member]	'	'
Assets	'	'
Cash and cash equivalents	0	5,253
Money Market Funds [Member] | Level I [Member]	'	'
Assets	'	'
Cash and cash equivalents	502	21,016
Money Market Funds [Member] | Level III [Member]	'	'
Assets	'	'
Cash and cash equivalents	0	0
Money Market Funds [Member] | Total [Member]	'	'
Assets	'	'
Cash and cash equivalents	$502	$21,016

Fair_Value_Measurement_Level_3

Fair Value Measurement (Level 3 Preferred Stock Warrant Liability) (Details) (Preferred Stock Warrant Liability [Member], USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Preferred Stock Warrant Liability [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'	'
Fair value at beginning of period	$412	$229
Reclassification to additional paid in capital upon the IPO	-410	0
Change in fair value recorded in other expense	-2	233
Fair value at end of period	$0	$462

Fair_Value_Measurement_Narrati

Fair Value Measurement (Narrative) (Details) (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Fair Value Disclosures [Abstract]	'
Fair value, assets, level 1 to level 2 transfers, amount	$0

Cash_and_Cash_Equivalents_Deta

Cash and Cash Equivalents (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
Cash and Cash Equivalents [Abstract]	'	'	'	'
Cash	$51,574,000	$4,000	'	'
Certificates of deposit	0	5,253,000	'	'
Money market funds	0	19,511,000	'	'
Total cash and cash equivalents	51,574,000	24,768,000	10,279,000	12,483,000
Investment in bank deposits	$4,500,000	'	'	'

Accounts_Receivable_and_Revenu2

Accounts Receivable and Revenues (Receivables and Allowance for Doubtful Accounts) (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Receivables [Abstract]	'	'
Accounts receivable	$7,617	$6,526
Less allowance for uncollectible accounts receivable	-1,106	-1,377
Accounts receivable, net	6,511	5,149
Allowance for Doubtful Accounts Receivable [Roll Forward]	'	'
Balance at beginning of period	1,377	1,676
Provision for bad debt expense	212	818
Write-off, net of recoveries	-483	-1,117
Balance at end of period	$1,106	$1,377

Accounts_Receivable_and_Revenu3

Accounts Receivable and Revenues (Revenues) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Receivables [Abstract]	'	'	'	'
Gross billings	$13,112	$13,985	$40,711	$42,692
Less contractual adjustments	-374	-421	-1,046	-1,451
Revenues	$12,738	$13,564	$39,665	$41,241

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	$24,899,000	'	$24,899,000	'	$23,135,000
Less accumulated depreciation	-12,319,000	'	-12,319,000	'	-11,642,000
Property and equipment, net	12,580,000	'	12,580,000	'	11,493,000
Depreciation	400,000	300,000	1,200,000	900,000	'
Gain (loss) on disposition of fixed assets	400,000	'	400,000	30,000	'
Retirement of fully depreciated assets	300,000	900,000	500,000	900,000	'
Laboratory Equipment [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	9,605,000	'	9,605,000	'	9,415,000
Office Equipment, Furniture and Fixtures [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	3,416,000	'	3,416,000	'	3,497,000
Leasehold Improvements [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	3,229,000	'	3,229,000	'	2,652,000
Software [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	2,154,000	'	2,154,000	'	1,793,000
Customer-Use Assets [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	328,000	'	328,000	'	0
Construction in Progress [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	$6,167,000	'	$6,167,000	'	$5,778,000

Restricted_Cash_Details

Restricted Cash (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Restricted Cash and Investments [Abstract]	'	'
Restricted cash	$502	$1,505

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Accrued wages and benefits	$2,072	$1,541
Accrued bonus	528	2,200
Other accrued liabilities	1,220	1,608
Total accrued expenses	$3,820	$5,349

LongTerm_Debt_and_Line_of_Cred2

Long-Term Debt and Line of Credit (Details) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Dec. 20, 2012

Dec. 20, 2012

Dec. 20, 2012

Dec. 20, 2012

Sep. 30, 2013

Dec. 20, 2012

Dec. 20, 2012

Sep. 30, 2013

Dec. 31, 2012

Dec. 20, 2012

Dec. 20, 2012

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Term Loan [Member]

Square 1 and Oxford Finance [Member]

Square 1 and Oxford Finance [Member]

Square 1 and Oxford Finance [Member]

Square 1 and Oxford Finance [Member]

Square 1 and Oxford Finance [Member]

Square 1 and Oxford Finance [Member]

Square 1 and Oxford Finance [Member]

Beginning [Member]

Over the Term of the Facility [Member]

Series E Redeemable Convertible Preferred Stock [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Term Loan [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term Debt

$15,788,000

$15,708,000

'

'

'

'

'

'

'

'

'

'

'

Long-term debt schedule:

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term debt to financial institutions

16,000,000

16,000,000

'

'

'

'

'

'

'

'

'

'

'

Less unamortized debt discount

-212,000

-292,000

'

'

'

'

'

'

'

'

'

'

'

Less current maturities of long-term debt

-3,904,000

0

'

'

'

'

'

'

'

'

'

'

'

Long-term debt, less current maturities and unamortized debt discount

11,884,000

15,708,000

'

'

'

'

'

'

'

'

'

'

'

Face value of long-term debt

'

'

'

'

'

'

'

'

'

'

'

'

16,000,000

New facility, borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

6,000,000

'

Number of shares called by warrants

'

'

'

'

'

'

'

'

73,564

'

'

'

'

Exercise price of warrants (in usd per share)

'

'

'

'

'

'

'

'

4.35

'

'

'

'

Fair value of warrants

'

'

'

'

'

'

'

200,000

'

'

'

'

'

Total unamortized debt issuance costs

'

'

'

'

'

'

74,000

'

'

'

'

'

'

Fixed annual interest rate

'

'

'

'

'

9.50%

'

'

'

'

'

'

'

Variable interest rate

'

'

6.25%

'

'

'

'

'

'

'

'

'

'

Description of variable rate basis

'

'

'institution's prime rate

'

'

'

'

'

'

'

'

'

'

Basis spread on variable rate, percent

'

'

3.00%

'

'

'

'

'

'

'

'

'

'

Revolving line of credit, amount outstanding

'

'

'

'

'

'

'

'

'

$0

$5,000,000

'

'

Minimum covenant ratio, liquidity

'

'

'

1.25

1

'

'

'

'

'

'

'

'

Net_Loss_Income_Per_Share_Anti

Net (Loss) Income Per Share (Anti-Dilutive Common Share Equivalents) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive common share equivalents	2,284,307	9,431,450	2,284,307	7,313,396
Convertible Preferred Stock (Series A, A-1, B, B-1, C, and C-1) [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive common share equivalents	0	1,222,211	0	1,222,211
Redeemable Convertible Preferred Stock (Series D, D-1, E and F) [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive common share equivalents	0	5,763,606	0	5,763,606
Common Stock Options and Warrants [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive common share equivalents	2,171,715	2,445,633	2,171,715	327,579
Restricted Stock Units [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive common share equivalents	112,592	0	112,592	0

Net_Loss_Income_Per_Share_Net_

Net (Loss) Income Per Share (Net (Loss) Income Per Share Calculation) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Numerator:	'	'	'	'
Net (loss) income	($4,627)	($481)	($9,919)	$1,057
Net (loss) income attributable to common stockholders – basic	-4,627	-481	-9,919	207
Net (loss) income attributable to common stockholders – diluted	-4,627	-481	-9,919	329
Denominator:	'	'	'	'
Weighted average common shares outstanding – basic (in shares)	14,727,286	1,704,689	14,727,286	1,704,689
Dilutive effect of common stock equivalent shares resulting from common stock options and warrants (in shares)	0	0	0	1,446,413
Weighted average common shares outstanding – diluted (in shares)	14,727,286	1,704,689	14,727,286	3,151,102
Net (loss) income per common share:	'	'	'	'
Net (loss) income per share attributable to common stockholders - basic (in usd per share)	($0.31)	($0.28)	($0.67)	$0.12
Net (loss) income per share attributable to common stockholders - diluted (in usd per share)	($0.31)	($0.28)	($0.67)	$0.10
Preferred Stock [Member]	'	'	'	'
Numerator:	'	'	'	'
Less: Undistributed earnings allocated	0	0	0	-850
Common Stock [Member]	'	'	'	'
Numerator:	'	'	'	'
Less: Undistributed earnings allocated	$0	$0	$0	$122

Equity_Transactions_and_ShareB2

Equity Transactions and Share-Based Compensation (Fair Value Assumptions) (Details)	9 Months Ended			12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012
	Stock Options [Member]	Stock Options [Member]	Series E and F Redeemable Convertible Preferred Stock [Member]	Series E and F Redeemable Convertible Preferred Stock [Member]	Series E and F Redeemable Convertible Preferred Stock [Member]	Series E and F Redeemable Convertible Preferred Stock [Member]
					Minimum [Member]	Maximum [Member]
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]	'	'	'	'	'	'
Expected term (in years)	'	'	'0 years	'	'3 months	'6 months
Risk-free interest rate	'	'	'	'	0.00%	0.10%
Expected volatility	'	'	'	30.00%	'	'
Expected dividend rate	'	'	'	0.00%	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions [Abstract]	'	'	'	'	'	'
Expected dividend yield	0.00%	0.00%	'	'	'	'
Risk-free interest rate	1.20%	0.80%	'	'	'	'
Expected volatility	45.50%	51.20%	'	'	'	'
Expected life (in years)	'5 years 9 months 18 days	'5 years 7 months 6 days	'	'	'	'

Equity_Transactions_and_ShareB3

Equity Transactions and Share-Based Compensation (Warrants) (Details)	Sep. 30, 2013
12/13/2006 [Member]	'
Class of Warrant or Right [Line Items]	'
Number of Shares	6,689
Exercise Price (in usd per share)	8.97
2/7/2008 [Member]	'
Class of Warrant or Right [Line Items]	'
Number of Shares	36,375
Exercise Price (in usd per share)	8.97
3/31/2011 [Member]	'
Class of Warrant or Right [Line Items]	'
Number of Shares	6,689
Exercise Price (in usd per share)	8.97
12/20/2012 [Member]	'
Class of Warrant or Right [Line Items]	'
Number of Shares	35,677
Exercise Price (in usd per share)	8.97

Equity_Transactions_and_ShareB4

Equity Transactions and Share-Based Compensation (Allocation of Share-based Compensation) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated share-based compensation expense	$513	$264	$1,065	$881
Cost of Revenues [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated share-based compensation expense	10	8	28	35
Research and Development [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated share-based compensation expense	132	89	372	359
Sales and Marketing [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated share-based compensation expense	73	44	163	198
General and Administrative [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated share-based compensation expense	$298	$123	$502	$289

Equity_Transactions_and_ShareB5

Equity Transactions and Share-Based Compensation (Stock Options by Exercise Price Range) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Total Options Outstanding, Number of Options (in shares)	2,086,285
Total Options Outstanding, Weighted Average Exercise Price	$6.09
Total Options Outstanding, Weighted Average Remaining Life in Years	'5 years 7 months
Options Exercisable, Number of Options (in shares)	1,592,387
Options Exercisable, Weighted Average Exercise Price	$5.34
Options Exercisable, Weighted Average Remaining Life in Years	'4 years 6 months
$1.87 – $2.45 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Range of Exercise Prices - Lower Limit	$1.87
Range of Exercise Prices - Upper Limit	$2.45
Total Options Outstanding, Number of Options (in shares)	281,522
Total Options Outstanding, Weighted Average Exercise Price	$2.36
Options Exercisable, Number of Options (in shares)	281,522
Options Exercisable, Weighted Average Exercise Price	$2.36
$2.49 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Range of Exercise Prices - Lower Limit	$2.49
Total Options Outstanding, Number of Options (in shares)	299,904
Total Options Outstanding, Weighted Average Exercise Price	$2.49
Options Exercisable, Number of Options (in shares)	299,904
Options Exercisable, Weighted Average Exercise Price	$2.49
$3.88 – $4.23 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Range of Exercise Prices - Lower Limit	$3.88
Range of Exercise Prices - Upper Limit	$4.23
Total Options Outstanding, Number of Options (in shares)	261,564
Total Options Outstanding, Weighted Average Exercise Price	$3.92
Options Exercisable, Number of Options (in shares)	261,564
Options Exercisable, Weighted Average Exercise Price	$3.92
$5.07 - $5.55 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Range of Exercise Prices - Lower Limit	$5.07
Range of Exercise Prices - Upper Limit	$5.55
Total Options Outstanding, Number of Options (in shares)	183,675
Total Options Outstanding, Weighted Average Exercise Price	$5.24
Options Exercisable, Number of Options (in shares)	79,334
Options Exercisable, Weighted Average Exercise Price	$5.14
$5.63 - $5.98 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Range of Exercise Prices - Lower Limit	$5.63
Range of Exercise Prices - Upper Limit	$5.98
Total Options Outstanding, Number of Options (in shares)	227,947
Total Options Outstanding, Weighted Average Exercise Price	$5.66
Options Exercisable, Number of Options (in shares)	193,045
Options Exercisable, Weighted Average Exercise Price	$5.63
$6.68 to $6.89 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Range of Exercise Prices - Lower Limit	$6.68
Range of Exercise Prices - Upper Limit	$6.89
Total Options Outstanding, Number of Options (in shares)	218,583
Total Options Outstanding, Weighted Average Exercise Price	$6.83
Options Exercisable, Number of Options (in shares)	152,418
Options Exercisable, Weighted Average Exercise Price	$6.85
$9.01 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Range of Exercise Prices - Lower Limit	$9.01
Total Options Outstanding, Number of Options (in shares)	74,134
Total Options Outstanding, Weighted Average Exercise Price	$9.01
Options Exercisable, Number of Options (in shares)	55,800
Options Exercisable, Weighted Average Exercise Price	$9.01
$9.65 - $9.84 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Range of Exercise Prices - Lower Limit	$9.65
Range of Exercise Prices - Upper Limit	$9.84
Total Options Outstanding, Number of Options (in shares)	236,334
Total Options Outstanding, Weighted Average Exercise Price	$9.68
Options Exercisable, Number of Options (in shares)	60,426
Options Exercisable, Weighted Average Exercise Price	$9.74
$11.11 - $11.44 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Range of Exercise Prices - Lower Limit	$11.11
Range of Exercise Prices - Upper Limit	$11.44
Total Options Outstanding, Number of Options (in shares)	222,793
Total Options Outstanding, Weighted Average Exercise Price	$11.40
Options Exercisable, Number of Options (in shares)	165,849
Options Exercisable, Weighted Average Exercise Price	$11.40
$12.80 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Range of Exercise Prices - Lower Limit	$12.80
Total Options Outstanding, Number of Options (in shares)	79,829
Total Options Outstanding, Weighted Average Exercise Price	$12.80
Options Exercisable, Number of Options (in shares)	42,525
Options Exercisable, Weighted Average Exercise Price	$12.80

Equity_Transactions_and_ShareB6

Equity Transactions and Share-Based Compensation (Narrative) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options issued during the period	511,443	'
Weighted average exercise price (in usd per share)	$8.01	'
Weighted average grant-date fair value (in usd per share)	$3.52	'
Stock issued upon exercise of stock options (in shares)	253,000	'
Weighted average exercise price upon exercise of stock options (in usd per share)	$2.58	'
Restricted Stock Units (RSUs) [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Award vesting percentage	100.00%	'
Number of shares granted	142,869	'
Weighted average grant date fair value (in usd per share)	$7.07	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	8,500	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$47,000	'
Unrecognized compensation expense, nonvested awards	600,000	'
Unrecognized compensation expense, nonvested awards, period for recognition	'2 years 8 months 12 days	'
Restricted Stock Units (RSUs) [Member] | Non-Employee Director [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Award vesting percentage	25.00%	'
Stock Options [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Unrecognized compensation expense, nonvested awards	1,600,000	'
Unrecognized compensation expense, nonvested awards, period for recognition	'2 years 4 months 24 days	'
Preferred Stock Warrant Liability [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Reclassification to additional paid in capital upon the IPO	$410,000	$0

RelatedParty_Transactions_Deta

Related-Party Transactions (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	12-May-97
			North Carolina State University [Member]
Related Party Transaction [Line Items]	'	'	'
Commitment to fund future collaborative research	'	'	$25,000
Due to Related Parties, Current	$2,500	$5,000	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Income Tax Disclosure [Abstract]	'	'
Provision or benefit for income taxes	$0	$0
Unrecognized tax benefits that would impact effective tax rate	$0	'
Effective income tax rate	0.00%	0.00%

Employee_Benefit_Plan_Details

Employee Benefit Plan (Details) (USD $)	0 Months Ended		3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Jul. 02, 2012	Jan. 02, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Postemployment Benefits [Abstract]	'	'	'	'	'	'
Employee minimum age	'	'	'	'	'21 years	'
Employee requisite service period	'	'	'	'	'30 days	'
Employer matching contribution, percent	50.00%	25.00%	'	'	'	'
Percent of employee's gross pay	6.00%	'	'	'	'	'
Employer matching contribution, amount	'	'	$0.20	$0.20	$0.50	$0.30

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
	sqft		sqft
Loss Contingencies [Line Items]	'	'	'	'	'
Area of leased office and laboratory space	83,000	'	83,000	'	'
Operating leases, rent expense	$300,000	$300,000	$800,000	$900,000	'
Property and equipment financed under capital leases:	'	'	'	'	'
Office equipment	182,000	'	182,000	'	182,000
Less accumulated depreciation	-182,000	'	-182,000	'	-182,000
Property and equipment under capital leases, net	0	'	0	'	0
Outstanding purchase obligation	4,400,000	'	4,400,000	'	'
Standby Letters of Credit [Member] | Letter of Credit [Member]	'	'	'	'	'
Loss Contingencies [Line Items]	'	'	'	'	'
Line of credit facility, current borrowing capacity	$500,000	'	$500,000	'	$1,500,000